Camptothecin derivative, method for preparing same and use thereof, antibody-drug conjugate, and use thereof

By developing new structure camptothecin derivatives and antibody-conjugated drugs, the low water solubility and side effects of existing camptothecin drugs have been solved, and the effect of improving the anti-tumor activity and safety of the drug has been achieved.

WO2024227432A1PCT designated stage expired Publication Date: 2024-11-07TAICHENGSI (SHANGHAI) BIOMEDICAL CO LTD

Patent Information

Application Number
PCT/CN2024/090645
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-30
Filing Date
2024-04-29
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

The existing camptothecin drugs have side effects such as hemotoxicity and adverse reactions in clinical applications, and their efficacy is limited by low water solubility, making it difficult to improve safety and effectiveness.

Method used

Develop camptothecin derivatives and their antibody-conjugated drugs with novel structures, improve the water-soluble and anti-tumor activity of drugs through specific compound structures and synthesis routes, and enhance their targeting and safety through antibody-conjugated technology.

Benefits of technology

The good anti-tumor activity and better safety of camptothecin derivatives are achieved, the side effects are reduced, and the targetedness and efficacy of the drug are improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024090645-FTAPPB-I100001
    Figure PCTCN2024090645-FTAPPB-I100001
  • Figure PCTCN2024090645-FTAPPB-I100002
    Figure PCTCN2024090645-FTAPPB-I100002
  • Figure PCTCN2024090645-FTAPPB-I100003
    Figure PCTCN2024090645-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to a camptothecin derivative, a method for preparing same and use thereof, an antibody-drug conjugate, and use thereof. The camptothecin derivative is a compound represented by general formula I, or a tautomer, a stereoisomer, a polymorph, a nitrogen oxide or an isotope-labeled form thereof. The camptothecin derivative and the antibody-drug conjugate of the present invention have good in-vitro cell-killing activity and a superior anti-tumor effect.
Need to check novelty before this filing date? Find Prior Art

Description

Camptothecin derivatives, preparation methods and uses thereof, antibody-drug conjugates and applications thereof Technical Field

[0001] The present invention relates to a camptothecin derivative with a novel structure, a preparation method and use thereof, an antibody-drug conjugate and application thereof. Background Art

[0002] Camptothecin (CPT) is an alkaloid extracted from the plant Camptotheca acuminata in the Davidiaceae family in the mid-1950s. It is a selective inhibitor of topoisomerase I (TopI), forming a stable ternary complex with topoisomerase I and cellular DNA through hydrogen bonding, preventing the broken DNA chains from reconnecting, thereby leading to DNA damage and cell apoptosis (Am J Cancer Res 2017; 7(12): 2350-2394).

[0003] Despite its wide therapeutic applications, camptothecin's efficacy is limited by its extremely low water solubility. Since its discovery, researchers have synthesized numerous camptothecin derivatives with enhanced water solubility and conducted biological evaluations of their anti-tumor properties. Currently, three camptothecin-based drugs have been approved for marketing: irinotecan for colorectal cancer, topotecan for ovarian cancer, and belotecan for ovarian cancer and small cell lung cancer. Other camptothecin derivatives under development include exatecan, rubitecan, chimmitecan, karenitecan, and diflomotecan.

[0004] Most camptothecin drugs or their derivatives cause side effects such as blood toxicity and adverse reactions of the digestive and urinary systems. In clinical studies, in addition to improving their pharmacokinetic properties, regulating activity or reducing dosage, methods to improve the safety and efficacy of camptothecin compounds also include forming antibody-drug conjugates with antibodies. For example, Exatecan has significant gastrointestinal toxicity and bone marrow toxicity, while the derivative DXd based on Exatecan has similar topoisomerase I inhibitory effects, but with lower bone marrow toxicity. On this basis, the DXd-based anti-HER2 antibody-drug conjugate DS8201 (Enhertu) was further developed. There is still a high clinical demand for anti-tumor drugs to develop new camptothecin derivatives and corresponding antibody-drug conjugates, and to further improve efficacy and improve safety.

[0005] Summary of the Invention

[0006] The present invention provides camptothecin derivatives with novel structures. The camptothecin compounds have good anti-tumor activity, and antibody-drug conjugates based thereon have the potential to be used for the treatment of tumor diseases.

[0007] In one aspect, the present invention provides a camptothecin derivative, characterized in that its structure is as shown in Formula I:

[0008] R1 and R2 are each independently selected from hydrogen, halogen, hydroxy, cyano, alkyl, alkoxy or cycloalkyl;

[0009] A is selected from hydrogen, amino, W is selected from cycloalkyl, Y is selected from -C(=O)-, -S(=O)2-, -CHCF3-, -C(=CH2)-, -P(=O)R 10 -、-C(=NR 11 )- or -C(=O)NH-; n=an integer from 0 to 4; Z is selected from hydrogen or -OH;

[0010] R3 in A is selected from hydrogen or alkyl;

[0011] R4 and R5 in A are the same or different and are independently selected from hydrogen, trifluoromethyl, alkyl, cycloalkyl, cycloalkyl-substituted alkyl, heterocyclyl, aryl or heteroaryl;

[0012] B is selected from hydrogen, hydroxy, hydroxy-substituted alkyl, alkanoyloxy-substituted alkyl, glycosyl-substituted alkyl, mercapto-substituted alkyl, amino-substituted alkyl, carboxyl-substituted alkyl, ester-substituted alkyl, alkynyl, alkenyl, cyano, or cyano-substituted alkyl;

[0013] R6 and R7 are the same or different and are independently selected from hydrogen, fluorine or alkyl;

[0014] R8 and R9 are the same or different and are independently selected from hydrogen, fluorine or alkyl;

[0015] R 10 and R 11 The same or different, and are independently selected from saturated or unsaturated alkyl and aryl groups.

[0016] According to one embodiment of the present invention, R1 and R2 are each independently selected from hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy or cycloalkyl;

[0017] A is selected from hydrogen, amino, Y is selected from -C(=O)-, -S(=O)2-, -CHCF3-, -C(=CH2)-, -P(=O)R 10 -、-C(=NR 11 )- or -C(=O)NH-; n=an integer from 0 to 4; Z is selected from hydrogen or -OH;

[0018] R3 in A is selected from hydrogen or alkyl;

[0019] R4 and R5 in A are the same or different and are independently selected from hydrogen, trifluoromethyl, alkyl, cycloalkyl, cycloalkyl-substituted alkyl, heterocyclyl, aryl or heteroaryl;

[0020] B is selected from hydrogen, hydroxy, hydroxy-substituted alkyl, alkanoyloxy-substituted alkyl, glycosyl-substituted alkyl, mercapto-substituted alkyl, amino-substituted alkyl, carboxyl-substituted alkyl, ester-substituted alkyl, alkynyl, alkenyl, cyano, or cyano-substituted alkyl;

[0021] R6 and R7 are the same or different and are independently selected from hydrogen, fluorine or alkyl;

[0022] R8 and R9 are the same or different and are independently selected from hydrogen, fluorine or alkyl;

[0023] R 10 and R 11 are the same or different and are independently selected from saturated or unsaturated alkyl or aryl groups.

[0024] According to one embodiment of the present invention, R1 is selected from fluorine; R2 is selected from methyl;

[0025] A is selected from hydrogen, amino, W is selected from cyclobutyl, Y is selected from -C(=O)-, -S(=O)2- or -CHCF3-; n is an integer from 0 to 3; Z is selected from hydrogen or -OH; R3 in A is selected from hydrogen or methyl;

[0026] R4 and R5 in A are the same or different and are independently selected from hydrogen, methyl, trifluoromethyl,

[0027] B is selected from hydrogen, -CH2OH, -CH2OAc, -CH2SH, -CH2NH2, -CH2C(=O)OH, -CH2C(=O)OMe, ethynyl, vinyl, cyano or -CH2CN;

[0028] R6 and R7 are the same or different and are independently selected from hydrogen or fluorine;

[0029] R8 and R9 are the same or different and are independently selected from hydrogen or fluorine.

[0030] According to an optional embodiment of the present invention, R4, R5 together with the carbon atom to which they are connected constitute a cyclopropyl group.

[0031] According to an optional solution of the present invention, R4 and R5 are not hydrogen at the same time.

[0032] According to an optional solution of the present invention, when B is hydrogen, A is also hydrogen; when A is amino, B is not hydrogen.

[0033] According to an optional solution of the present invention, in said A, Y is selected from -C(=O)-; n=0 or 1.

[0034] According to an optional embodiment of the present invention, R3, B in A, and the carbon atom to which A and B are commonly connected and / or the nitrogen atom to which R3 is connected constitute an aziridine group or an azetidine group, and / or R1 and R2 and their respective adjacent carbon atoms constitute a cycloalkyl group or a heterocyclic group, and / or R4 and R5 together with the carbon atom to which they are commonly connected constitute a cycloalkyl group or a heterocycloalkyl group.

[0035] According to a preferred embodiment of the present invention, in the general formula I:

[0036] A is selected from hydrogen, amino or Y is selected from -C(=O)-; n=0-4; Z is selected from hydrogen or -OH;

[0037] B is selected from hydrogen, hydroxy, hydroxy-substituted alkyl, alkanoyloxy-substituted alkyl, glycosyl-substituted alkyl, mercapto-substituted alkyl, amino-substituted alkyl, carboxyl-substituted alkyl, ester-substituted alkyl, alkynyl, alkenyl, cyano, or cyano-substituted alkyl;

[0038] R1 and R2 are each independently selected from hydrogen, halogen, hydroxy, cyano, alkyl, alkoxy, cycloalkyl;

[0039] R3 in A is selected from hydrogen or alkyl;

[0040] R4 and R5 in A are the same or different and are independently selected from hydrogen, trifluoromethyl, alkyl, cycloalkyl, cycloalkyl-substituted alkyl, heterocyclyl, aryl or heteroaryl; R4 and R5 are not hydrogen at the same time;

[0041] R6 and R7 are the same or different and are independently selected from hydrogen, fluorine or alkyl;

[0042] R8 and R9 are the same or different and are independently selected from hydrogen, fluorine or alkyl.

[0043] According to an optional embodiment of the present invention, B and R3 in A and the carbon atom and nitrogen atom to which A and B are commonly connected constitute aziridine or azetidine, and / or R1 and R2 and their respective adjacent carbon atoms constitute a cycloalkyl or heterocyclic group, and / or R4, R5 and the carbon atom to which they are commonly connected constitute a cycloalkyl or heterocycloalkyl group.

[0044] Further preferably, the compound of general formula I is selected from at least one of the structures shown below:

[0045] According to one embodiment of the present invention, the present invention also includes a prodrug of the compound of formula I, or a pharmaceutically acceptable salt, ester, solvate, tautomer, stereoisomer, polymorph, nitrogen oxide or isotope label thereof.

[0046] Another aspect of the present invention provides use of the aforementioned camptothecin derivatives in the preparation of drugs for treating cancer.

[0047] Another aspect of the present invention provides a compound of formula II:

[0048] Wherein, M is selected from and / or,

[0049] L1 is selected from n1=an integer from 1 to 10, n2=an integer from 1 to 12, n3=an integer from 1 to 10, n4=an integer from 1 to 12; and / or,

[0050] L2 is selected from n5=an integer of 7-24, L2 is connected to A in the general formula I; or

[0051] L2 is selected from L2 is connected to the O of -OH in general formula I;

[0052] D is selected from the product group formed by the aforementioned camptothecin derivative losing one or more atoms or groups, that is, the product group formed by the compound of general formula I or its prodrug, pharmaceutically acceptable salt, ester, solvate, tautomer, stereoisomer, polymorph, nitrogen oxide or isotope label losing one or more atoms or groups.

[0053] In the general formula II, one or two of L1 and L2 are selected.

[0054] According to one embodiment of the present invention, M is selected from

[0055] According to one embodiment of the present invention, L1 is selected from

[0056] According to one embodiment of the present invention, L2 is selected from

[0057] L2 is connected to A in the general formula I.

[0058] According to one embodiment of the present invention,

[0059] L2 is selected from L2 is connected to the O of -OH in the general formula I.

[0060] According to one embodiment of the present invention, the compound of formula II is at least one of the following structures, wherein L2 is connected to A in formula I:

[0061] Alternatively, the compound of formula II is selected from the structure shown below, wherein L2 is connected to the O of -OH in formula I:

[0062] According to one embodiment of the present invention, the present invention also includes prodrugs, pharmaceutically acceptable salts, esters, solvates, tautomers, stereoisomers, polymorphs, nitrogen oxides or isotope labels of the compound of formula II.

[0063] Another aspect of the present invention provides use of the aforementioned compound in preparing a drug for treating cancer.

[0064] Another aspect of the present invention provides an antibody-drug conjugate of formula III:

[0065] Wherein Ab is an antibody, an antibody fragment or a protein, wherein the antibody is selected from a mouse antibody, a rabbit antibody, a phage display antibody, a yeast display antibody, a chimeric antibody, a humanized antibody, a fully human antibody, an antibody fragment, a bispecific antibody and a multispecific antibody; M-L1-L2-D is selected from any compound of the aforementioned general formula II, or a prodrug, a pharmaceutically acceptable salt, an ester, a solvate, a tautomer, a stereoisomer thereof, a polymorph, a nitrogen oxide or an isotope label thereof; and n6 is selected from any value between 1 and 20.

[0066] In the general formula III, the carbon-carbon double bond of M in the M-L1-L2-D is connected to the sulfhydryl group in the antibody Ab by Michael addition reaction to form a CS bond.

[0067] According to one embodiment of the present invention, the antibody is a monoclonal antibody, selected from the group consisting of, but not limited to: Abciximab, Alemtuzumab, Anetumab, Atezolizumab, Avelumab, Basiliximab, Bevacizumab, Blinatumumab, Brentuximab, Catumaxomab, Cetuximab, Cirmtuzumab, Coltuximab, Daclizumab, Daratumumab, mumab), Denintuzumab, Denosumab, Depatuxizumab, Dinutuximab, Durvalumab, Elotuzumab, Enfortumab, Glembatumumab, Gemtuzumab, Ibritumomab, Indatuximab, Indusatumab, Inotuzumab, Ipilimumab, Labetuzumab, LatuzumabLadiratuzumab, Laprituximab, Lifastuzumab, Lorvotuzumab, Milatuzumab, Mirvetuximab, Naratuximab, Necitumumab, Nimotuzumab, Nivolumab, Obinutuzumab, Ofatumumab, Olaratumab, Omalizumab, Palivizumab, Panitumumab, Patritumab, Pembrolizumab, Pertuzumab b), Pinatuzumab, Polatuzumab, Ramucirumab, Rovalpituzumab, Sacituzumab, Siltuximab, Sirtratumab, Sofituzumab, Vadastuximab, Vorsetuzumab, Trastuzumab, anti-CD4 antibody, anti-CD5 antibody, anti-CD13 antibody and anti-CD30 antibody or antigen-binding fragment or immunologically active portion thereof; M-L1-L2-D is selected from the aforementioned compound, or a prodrug, pharmaceutically acceptable salt, ester, solvate, tautomer, stereoisomer, polymorph, nitrogen oxide or isotope label thereof; n6 is selected from any value between 4 and 10.

[0068] According to one embodiment of the present invention, the antibody is a monoclonal antibody, selected from, but not limited to: Patritumab, Sacituzumab, Mirvetuximab, Cetuximab, Trastuzumab, Cirmtuzumab; M-L1-L2-D is selected from the aforementioned compounds, or prodrugs, pharmaceutically acceptable salts, esters, solvates, tautomers, stereoisomers, polymorphs, nitrogen oxides or isotope labels of the compounds; n6 is selected from any value between 4 and 8.

[0069] According to one embodiment of the present invention, the conjugate is selected from at least one of the structures shown in the following formula:

[0070] Where n6 is any value between 4 and 8.

[0071] Another object of the present invention is to provide the camptothecin derivatives, their prodrugs, pharmaceutically acceptable salts, esters, solvates, tautomers, stereoisomers, polymorphs, nitrogen oxides and isotope labels described in the present invention for use in treating cancer, preferably treating sarcoma, lung cancer, ovarian cancer, gastric cancer, colorectal cancer and breast cancer.

[0072] Another object of the present invention is to provide the antibody-drug conjugate based on camptothecin derivatives of the present invention for use in treating cancer, preferably treating sarcoma, lung cancer, ovarian cancer, gastric cancer, colorectal cancer and breast cancer.

[0073] The camptothecin derivatives and antibody-drug conjugates of the present invention have good in vitro cell-killing activity and better anti-tumor effects.

[0074] Another object of the present invention is to provide a method for synthesizing the aforementioned camptothecin derivatives.

[0075] The compounds of the general formula I-1-1 and I-1-2 in the present invention can be synthesized by the following synthetic routes.

[0076] Wherein, R1, R2, R6, R7, R8 and R9 have the same meanings as above;

[0077] Step 1

[0078] The compound of general formula I-intermediate 1 is obtained by a substitution reaction of the compound of general formula I-raw material 1.

[0079] In some embodiments, this step is carried out at a suitable temperature in the range of -15°C to 55°C, which may be -10°C, -5°C, 0°C, 5°C, 10°C, 25°C, 50°C, preferably -5°C to 5°C.

[0080] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane and n-hexane, preferably N,N-dimethylformamide.

[0081] In some embodiments, this step is carried out under alkaline conditions, and the reagent providing alkaline conditions includes but is not limited to one or more of potassium carbonate, sodium carbonate, cesium carbonate, potassium tert-butoxide, sodium hydride, n-butyl lithium, lithium diisopropylamide, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide and potassium bistrimethylsilylamide, preferably cesium carbonate.

[0082] Step 2

[0083] The compound of general formula I-intermediate 2 is obtained by hydrolyzing the compound of general formula I-intermediate 1.

[0084] In some embodiments, this step is carried out at a suitable temperature in the range of -15°C to 55°C; the temperature may be -10°C, -5°C, 0°C, 5°C, 10°C, 25°C, 50°C; preferably 20°C to 40°C.

[0085] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane, n-hexane and ethyl acetate, preferably methanol;

[0086] In some embodiments, this step is carried out under acidic conditions, and the reagent providing acidic conditions includes but is not limited to one or more of hydrochloric acid, trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, formic acid and sulfuric acid, preferably hydrochloric acid.

[0087] Step 3

[0088] The compounds of the general formula I-intermediate 3-1 and the general formula I-intermediate 3-2 are obtained by a cyclization reaction between the compound of the general formula I-intermediate 2 and (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyran[3,4-f]indolizine-3,6,10(4H)-trione.

[0089] In some embodiments, this step is carried out at a suitable temperature in the range of 15°C to 150°C; the temperature may be 20°C, 25°C, 40°C, 50°C, 60°C, 100°C, 130°C, 140°C; preferably, the temperature range is 110°C to 140°C;

[0090] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of toluene, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane, n-hexane and ethyl acetate, preferably toluene;

[0091] In some embodiments, this step is carried out under acidic conditions, and the reagent providing acidic conditions is selected from one or more of p-toluenesulfonic acid, hydrochloric acid, trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, formic acid and sulfuric acid, preferably methanesulfonic acid.

[0092] Step 4

[0093] The compounds of the general formula I-1-1 and the general formula I-1-2 are obtained by hydrolyzing the compounds of the general formula I-intermediate 3-1 and the general formula I-intermediate 3-2.

[0094] In some embodiments, this step is carried out at a suitable temperature in the range of 15°C to 150°C, wherein the temperature is 20°C, 25°C, 40°C, 50°C, 60°C, 100°C, 130°C, or 140°C; preferably, the temperature range is 110°C to 140°C;

[0095] In some embodiments, this step is carried out under acidic conditions, and the reagent providing acidic conditions is selected from one or more of p-toluenesulfonic acid, hydrochloric acid, trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, formic acid and sulfuric acid, preferably methanesulfonic acid.

[0096] The compounds of the general formula I-2-1 and I-2-2 in the present invention can be synthesized by the following synthetic routes.

[0097] Wherein, R1, R2, R6, R7, R8 and R9 have the same meanings as above;

[0098] Step 1

[0099] The compound of general formula I-intermediate 4 is obtained by a substitution reaction of the compound of general formula I-raw material 1.

[0100] In some embodiments, this step is carried out at a suitable temperature in the range of -15°C to 55°C; the temperature may be -10°C, -5°C, 0°C, 5°C, 10°C, 25°C, 50°C; preferably -5°C to 5°C.

[0101] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane and n-hexane, preferably tetrahydrofuran.

[0102] In some embodiments, this step is carried out under alkaline conditions, and the reagent providing alkaline conditions is selected from one or more of potassium carbonate, sodium carbonate, cesium carbonate, potassium tert-butoxide, sodium hydride, n-butyl lithium, lithium diisopropylamide, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide and potassium bistrimethylsilylamide, preferably sodium hydride.

[0103] Step 2

[0104] The compound of the general formula I-intermediate 5 is obtained by a 1,2-elimination reaction of the compound of the general formula I-intermediate 4.

[0105] In some embodiments, this step is carried out at a suitable temperature in the range of 15°C to 150°C; the temperature may be 20°C, 25°C, 40°C, 50°C, 60°C, 100°C, 130°C, 140°C; preferably, the temperature range is 120°C to 150°C.

[0106] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of toluene, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane, n-hexane and ethyl acetate, preferably toluene.

[0107] Step 3

[0108] The compound of the general formula I-intermediate 6 is obtained by hydrolyzing the compound of the general formula I-intermediate 5.

[0109] In some embodiments, this step is carried out at a suitable temperature in the range of -5°C to 110°C, which may be 0°C, 10°C, 25°C, 50°C, 70°C, 80°C, or 100°C, preferably in the range of 60°C to 90°C.

[0110] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane, n-hexane and ethyl acetate, preferably methanol.

[0111] In some embodiments, this step is carried out under acidic conditions, and the reagent providing acidic conditions is selected from one or more of hydrochloric acid, trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, formic acid and sulfuric acid, preferably hydrochloric acid.

[0112] Step 4

[0113] The compounds of the general formula I-intermediate 7-1 and the general formula I-intermediate 7-2 are obtained by a cyclization reaction between the compound of the general formula I-intermediate 6 and (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyran[3,4-f]indolizine-3,6,10(4H)-trione.

[0114] In some embodiments, this step is carried out at a suitable temperature ranging from 15°C to 150°C, which may be 20°C, 25°C, 40°C, 50°C, 60°C, 100°C, 130°C, or 140°C, preferably ranging from 110°C to 150°C.

[0115] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of toluene, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane, n-hexane and ethyl acetate, preferably toluene.

[0116] In some embodiments, this step is carried out under acidic conditions, and the reagent providing acidic conditions is selected from one or more of p-toluenesulfonic acid, hydrochloric acid, trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, formic acid and sulfuric acid, preferably p-toluenesulfonic acid.

[0117] Step 5

[0118] The compounds of the general formula I-2-1 and the general formula I-2-2 are obtained by hydrolyzing the compounds of the general formula I-intermediate 7-1 and the general formula I-intermediate 7-2.

[0119] In some embodiments, this step is carried out at a suitable temperature in the range of 15°C-150°C, which can be 20°C, 25°C, 40°C, 50°C, 60°C, 100°C, 130°C, 140°C, and preferably in the range of 110°C-150°C.

[0120] In some embodiments, this step is carried out under acidic conditions, and the reagent providing acidic conditions is selected from one or more of p-toluenesulfonic acid, hydrochloric acid, trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, formic acid and sulfuric acid, preferably methanesulfonic acid.

[0121] Alternatively, the compound of formula I-3 in the present invention can be synthesized by the following synthetic route.

[0122] Wherein, R1, R2, R8 and R9 have the same meanings as described above;

[0123] Step 1

[0124] The compound of the general formula I-intermediate 8 is obtained by a deoxyfluorination reaction of the compound of the general formula I-raw material 2.

[0125] In some embodiments, this step is carried out at a suitable temperature in the range of -5°C to 120°C, such as 0°C, 10°C, 25°C, 50°C, 70°C, 80°C, or 100°C; preferably, the temperature range is 60°C to 90°C.

[0126] In some embodiments, this step is carried out in a suitable fluorination agent, which can be selected from one or more of DAST, Deoxo-Fluor, TFEDMA, XtalFluor, FluoLead, PhenoFluor, BPSF, PyFluor and SulfoxFluor, preferably DAST.

[0127] Step 2

[0128] The compound of the general formula I-intermediate 9 is obtained by reducing the compound of the general formula I-intermediate 8.

[0129] In some embodiments, this step is carried out at a suitable temperature in the range of 15°C-120°C, such as 20°C, 25°C, 40°C, 50°C, 60°C, 70°C, 90°C, 100°C; preferably, the temperature range is 60°C-90°C.

[0130] In some embodiments, this step is carried out in the presence of a suitable reducing agent, which can be selected from one or more of palladium catalysts, platinum catalysts, rhodium catalysts, iron powder, zinc powder, stannous chloride, nickel catalysts, hydrosulfite and titanium trichloride, preferably iron powder.

[0131] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of toluene, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane, n-hexane and ethyl acetate, preferably methanol.

[0132] Step 3

[0133] The compound of the general formula I-intermediate 10 is obtained by condensation reaction of the compound of the general formula I-intermediate 9.

[0134] In some embodiments, this step is carried out at a suitable temperature in the range of -5°C to 60°C, such as 0°C, 5°C, 10°C, 25°C, or 50°C; preferably, the temperature range is 10°C to 30°C.

[0135] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of tetrahydrofuran, 1,4-dioxane, dichloromethane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane and n-hexane, preferably dichloromethane.

[0136] In some embodiments, this step is carried out in a suitable base, including but not limited to one or more of potassium carbonate, sodium carbonate, cesium carbonate, sodium hydride, sodium hydroxide, DIPEA, triethylamine, potassium tert-butoxide and pyridine, preferably DIPEA.

[0137] Step 4

[0138] The compound of the general formula I-intermediate 11 is obtained by oxidation reaction of the compound of the general formula I-intermediate 10.

[0139] In some embodiments, this step is performed at a suitable temperature in the range of -5°C to 60°C, wherein the temperature is 0°C, 5°C, 10°C, 25°C, 50°C, preferably 25°C.

[0140] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from tetrahydrofuran, 1,4-dioxane, dichloromethane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, acetone, n-hexane, preferably acetone.

[0141] In some embodiments, this step is carried out in a suitable oxidizing agent, including but not limited to potassium permanganate, chromium trioxide, hydrogen peroxide, tert-butyl hydroperoxide, pyridinium chlorochromate, sodium dichromate, DDQ, pyridinium dichromate, Jones reagent, manganese dioxide, ceric ammonium nitrate, preferably potassium permanganate.

[0142] Step 5

[0143] The compound of the general formula I-intermediate 12 is obtained by hydrolyzing the compound of the general formula I-intermediate 11.

[0144] In some embodiments, this step is carried out at a suitable temperature, such as 0°C, 10°C, 25°C, 50°C, 70°C, 80°C, or 100°C; preferably, the temperature range is 10°C-30°C.

[0145] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane, n-hexane and ethyl acetate, preferably methanol.

[0146] In some embodiments, this step is carried out under acidic conditions, and the reagent providing acidic conditions is selected from one or more of hydrochloric acid, trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, formic acid and sulfuric acid, preferably hydrochloric acid.

[0147] Step 6

[0148] The compound of general formula I-3 is obtained by a cyclization reaction between the compound of general formula I-intermediate 12 and (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyran[3,4-f]indolizine-3,6,10(4H)-trione.

[0149] In some embodiments, this step is carried out at a suitable temperature in the range of 15°C-150°C, such as 20°C, 25°C, 40°C, 50°C, 60°C, 100°C, 130°C, 140°C; preferably, the temperature range is 110°C-150°C.

[0150] In some embodiments, this step is carried out in a suitable organic solvent, which can be selected from one or more of toluene, methanol, ethanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, n-heptane, n-hexane and ethyl acetate, preferably toluene.

[0151] In some embodiments, this step is carried out under acidic conditions, and the reagent providing acidic conditions is selected from one or more of p-toluenesulfonic acid, hydrochloric acid, trifluoroacetic acid, trifluoromethanesulfonic acid, methanesulfonic acid, formic acid and sulfuric acid, preferably p-toluenesulfonic acid. DETAILED DESCRIPTION

[0152] Table 1: Examples of specific compounds of formula II

[0153] Synthesis of compounds

[0154] The following are examples of the synthesis and analysis of the compounds described in this patent (including intermediates, toxins, linkers and toxin linkers). It must be noted that the following examples are only some embodiments and the present invention is not limited to the examples currently described.

[0155] 1. Camptothecin derivatives

[0156] Example 1: Synthesis of P1 and P16

[0157] (9S)-1-Amino-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione methanesulfonate.

[0158] Step 1: Synthesis of N,N'-(3-fluoro-7-(fluoromethyl)-4-methyl-8-oxo-5,6,7,8-tetrahydronaphthalene-1,7-diyl)diacetamide.

[0159] To a solution of N,N'-(3-fluoro-4-methyl-8-oxo-5,6,7,8-tetrahydronaphthalene-1,7-diyl)diacetamide (4.38 g, 15.00 mmol) in DMF (45 mL, 100%) was added Cs2CO3 (7.33 g, 22.50 mmol) at 0°C. After 30 minutes, ICH2F (6.0 g, 37.50 mmol) was added thereto. After the addition was complete, the mixture was stirred at room temperature for 2 hours. LCMS showed that the reaction was complete. The mixture was heated to 40 ℃ and dried over a temperature of 100 ℃ for 10 minutes. The product was diluted with H2O (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic phase was separated, washed with saturated brine (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated to obtain the product, which was purified by silica gel flash column chromatography (0-50% ethyl acetate in petroleum ether) to obtain N,N'-(3-fluoro-7-(fluoromethyl)-4-methyl-8-oxo-5,6,7,8-tetrahydronaphthalene-1,7-diyl) diacetamide (2.5 g, 51% yield) as a brown solid.

[0160] LC-MS (ESI) m / z: 325.2 [M+H] + .

[0161] Step 2: Synthesis of N-(8-amino-6-fluoro-2-(fluoromethyl)-5-methyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide.

[0162] To a solution of N,N'-(3-fluoro-7-(fluoromethyl)-4-methyl-8-oxo-5,6,7,8-tetrahydronaphthalene-1,7-diyl)diacetamide (0.50 g, 1.54 mmol) in H2O (5.00 mL) was added 2N HCl / MeOH (5.00 mL) at 0°C. After the addition was complete, the mixture was stirred at room temperature under N2 protection for 2 hours. LCMS showed that the reaction was complete. The mixture was concentrated to give a crude product, which was purified by silica gel flash column chromatography (0-50% ethyl acetate in petroleum ether) to give N-(8-amino-6-fluoro-2-(fluoromethyl)-5-methyl-1-oxo-1,2,3,4-tetrahydronaphthalene-2-yl)acetamide (150 mg, 34% yield) as a yellow solid.

[0163] LC-MS (ESI) m / z: 283.2 [M+H] + .

[0164] Step 3: Synthesis of (9'S)-1-acetyl-9'-ethyl-5'-fluoro-9'-hydroxy-4'-methyl-12',15'-dihydro-2'-hydrospiro[aziridine-2'-benzopyrano[3',4':6,7]indolizine[1,2-b]quinoline]-10',13'(3'H,9'H)-dione.

[0165] To a solution of N-(8-amino-6-fluoro-2-(fluoromethyl)-5-methyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide (150 mg, 0.53 mmol) and (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (167 mg, 0.63 mmol) in toluene (20.0 mL, 100%) was added MsOH (10.18 mg, 0.10 mmol) and AcOH (34.98 mg, 0.58 mmol). The reaction mixture was stirred at 130° C. for 12 hours. LCMS showed the reaction was complete. The reaction solution was cooled to room temperature and concentrated to give a crude product, which was purified by silica gel flash column chromatography (0-10% methanol in dichloromethane) to give (9'S)-1-acetyl-9'-ethyl-5'-fluoro-9'-hydroxy-4'-methyl-12',15'-dihydro-2'-hydropyrano[aziridine-2'-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline]-10',13'(3'H,9'H)-dione (20 mg, 7% yield) as a brown solid.

[0166] LC-MS (ESI) m / z: 490.2 [M+H] + .

[0167] Step 4: Synthesis of (9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-2,3,12,15-tetrahydrobenzopyrano[3',4':6,7]indolizine[1,2-b]quinoline-10,13(1H,9H)-dione.

[0168] To a solution of (9'S)-1-acetyl-9'-ethyl-5'-fluoro-9'-hydroxy-4'-methyl-12',15'-dihydro-2'-pyrano[aziridine-2'-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline]-10',13'(3'H,9'H)-dione (20.00 mg, 0.04 mmol) in H2O (0.50 mL) was added MsOH (1.00 mL) at 0°C. After the addition was complete, the mixture was stirred at 130°C for 12 hours. LCMS indicated the reaction was complete. The mixture was concentrated to give the product, which was purified by reverse phase flash chromatography (0-70% acetonitrile in H2O) to afford (9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-2,3,12,15-tetrahydrobenzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(1H,9H)-dione (1.68 mg, 7% yield) as a light yellow solid.

[0169] Characterization data of P1:

[0170] LC-MS (ESI) m / z: 466.0 [M+H] + .

[0171] 1 H NMR (400MHz, CD3OD) δ7.79-7.73(m,1H),7.67(d,J=2.8Hz,1H),5.72-5.60(m,2H),5.54-5.40(m,2H),4.15-3.93(m,2H),3.4 8-3.36(m,1H),3.31-3.20(m,1H),2.82-2.74(m,1H),2.49(s,3H),2.44-2.32(m,1H),2.05-1.90(m,2H),1.08-1.00(m,3H).

[0172] Example 2: Synthesis of P2, P3, P17, and P18

[0173] (1R, 9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzopyrano[3',4':6,7]indolizine[1,2-b]quinoline-10,13-dione and (1S, 9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzopyrano[3',4':6,7]indolizine[1,2-b]quinoline-10,13-dione.

[0174] Step 1: Synthesis of (1'S, 9'S)-1-acetyl-9'-ethyl-5'-fluoro-9'-hydroxy-4'-methyl-12', 15'-dihydro-2'-pyrano[aziridine-2,1'-benzopyrano[3', 4': 6,7]indolizine[1,2-b]quinoline]-10', 13'(3'H, 9'H)-dione and (1'R, 9'S)-1-acetyl-9'-methyl-5'-fluoro-9'-hydroxy-4'-methyl-12', 15'-dihydro-2'H-pyrano]aziridine-2,1'-benzopyrano[3', 4': 6,7]indolizine[1,2-b]quinoline]-10', 13'(3'H, 9'H)-dione.

[0175] N-(8-amino-6-fluoro-2-(fluoromethyl)-5-methyl-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide (1.10 g, 3.88 mmol), (S)-4-ethyl-4-hydroxy-7,8-dihydro-1h-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (1.23 g, 4.66 mmol) in toluene (80.00 mL), MsOH (74.5 mg, 0.77 mmol), and AcOH (256 mg, 4.3 mmol) were added. The reaction mixture was stirred at 130° C. for 12 hours. LCMS showed that the reaction was complete. The reaction solution was cooled to room temperature and concentrated to obtain the product, which was purified by silica gel chromatography (0-4% MeOH in DCM) to afford (1',9')-1-acetyl-9'-ethyl-5'-fluoro-9'-hydroxy-4'-methyl-12',15'-dihydro-2'-spiro[azapyridine-2,1'-benzo]pyrano[3',4':6,7]indolizine[1,2-b]quinoline]-10',13'(3'h,9'H)-dione P17 (100 mg, 5%) The product was a yellow solid and (1'r,9')-1-acetyl-9'-ethyl-5'-fluoro-9'-hydroxy-4'-methyl-12',15'-dihydro-2'-spiro[azapyridine-2,1'-chromeno[3',4':6,7]indolizino[1,2-b]quinoline]-10',13'(3'h,9'H)-dione P18 (95 mg, 5% yield) was a yellow solid.

[0176] Characterization data of P17:

[0177] LC-MS (ESI) m / z: 490.2 [M+H] + .

[0178] 1 H NMR (400MHz, DMSO-d6) δ7.74(d,J=10.8Hz,1H),7.29(d,J=8.8Hz,1H),6.50( d,J=3.2Hz,1H),5.40(s,2H),5.25(d,J=18.0Hz,1H),5.08(d,J=18.0Hz,1H) ,4.59(d,J=9.2Hz,1H),4.18(d,J=8.8Hz,1H),3.19-3.03(m,1H),2.37(s,3H ), 2.16 (s, 3H), 2.14-2.06 (m, 2H), 1.93-1.77 (m, 3H), 0.88 (t, J = 7.2Hz, 3H).

[0179] Characterization data of P18:

[0180] LC-MS (ESI) m / z: 490.2 [M+H] + .

[0181] 1 H NMR (400MHz, DMSO-d6) δ7.77(d,J=10.8Hz,1H),7.29(s,1H),6.51(s,1H),5.41(s,2H),5.30-5.01(m,2H),4.63-4.54(m,1H),4.17-4 .15(m,1H),3.13-3.05(m,1H),2.38(s,3H),2.16(s,3H),2.16-2.10(m,1H),1.99-1.98(m,1H),1.87-1.84(m,3H),0.90-0.83(m,3H).

[0182] Step 2: Synthesis of (1R,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-2,3,12,15-tetrahydrochromeno[3',4':6,7]indolizino[1,2-b]quinoline-10,13(1H,9H)-dione.

[0183] To a solution of (1'S,9'S)-1-acetyl-9'-ethyl-5'-fluoro-9'-hydroxy-4'-methyl-12'-, 15'-dihydro-2'-spiro[aziridine-2'-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinoline]-10'-, 13'(3'H,9'H)-dione (20 mg, 0.04 mmol) in H2O (0.5 mL) was added MsOH (1.0 mL) at 0°C. After addition, the mixture was stirred at 130°C for 12 hours. LCMS showed that the reaction was complete. The mixture was concentrated to give the product, which was purified by C 18 Purification with (0-70% ACN in H2O) gave (1R,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-2,3,12,15-tetrahydrobenzopyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(1H,9H)-dione (12 mg, 63% yield) as a light yellow solid.

[0184] Characterization data of P3:

[0185] LC-MS (ESI) m / z: 466.4 [M+H] + .

[0186] 1H NMR (400MHz, CD3OD) δ7.81 (d, J = 10.4Hz, 1H), 7.69 (s, 1H), 5.68-5.60 (m, 2H), 5.47-5.41 (m, 2H), 4.04-3.98 (m, 2H), 3.42- 3.36(m,1H),3.25-3.21(m,1H),2.80-2.73(m,1H),2.49(s,3H),2.41-2.32(m,1H),2.03-1.94(m,2H),1.05-1.01(m,3H).

[0187] Step 3: Synthesis of (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-2,3,12,15-tetrahydrochromeno[3',4':6,7]indolizino[1,2-b]quinoline-10,13(1H,9H)-dione.

[0188] To a solution of (1'R,9'S)-1-acetyl-9'-ethyl-5'-fluoro-9'-hydroxy-4'-methyl-12'-, 15'-dihydro-2'-spiro[aziridine-2'-benzopyrano[3',4':6,7]indolizino[1,2-b]quinoline]-10'-, 13'(3'H,9'H)-dione (20 mg, 0.04 mmol) in H2O (0.5 mL) was added MsOH (1.0 mL) at 0°C. After addition, the mixture was stirred at 130°C for 12 hours. LCMS showed that the reaction was complete. The mixture was concentrated to give the product, which was purified by C 18 Purification with (0-70% ACN in H2O) gave (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-2,3,12,15-tetrahydrobenzopyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(1H,9H)-dione (7.0 mg, 37% yield) as a white solid.

[0189] Characterization data of P2:

[0190] LC-MS (ESI) m / z: 466.4 [M+H] + .

[0191] 1H NMR (400MHz, CD3OD) δ7.65-7.62(m,2H),5.82-5.38(m,1H),5.60-5.53(m,2H),5.39-5.35(m,1H),3.76-3.64(m,2H),3.42 -3.31(m,1H),3.20-3.03(m,1H),2.53-2.51(m,1H),2.41(s,3H),2.09-2.07(m,1H),1.96-1.94(m,1H),1.00-0.97(m,3H).

[0192] Example 3: Synthesis of P8

[0193] ((1S, 9S) -1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1,2,3,9,10,12,13,15-octahydrobenzopyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl) methyl acetate 2,2,2-trifluoroacetate.

[0194] Synthesis of P8

[0195] At 0 ° C, to (1'S, 9'S) -1-acetyl -9'- ethyl -5'- fluoro -9'- hydroxy -4'- methyl -12'-, 15'- dihydro -2'- spiro [aziridine -2'- benzopyrano [3', 4': 6,7] indolizine [1,2-b] quinoline] -10'-, 13' (3'H, 9'H) - dione (10 mg, 0.02 mmol) in H2O (0.5 mL) and acetonitrile (2 mL) was added TFA (0.5 mL). After addition, the mixture was stirred at 25 ° C for 2 hours. LCMS showed that the reaction was complete. The mixture was concentrated to give the product, which was purified using C18 (0-70% acetonitrile in H2O) to give ((1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1,2,3,9,10,12,13,15-octahydrobenzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)acetate methyl 2,2,2-trifluoroacetate (5.95 mg, 47% yield) as a light yellow solid.

[0196] Characterization data of P8:

[0197] LC-MS (ESI) m / z: 507.7 [M+H] + .

[0198] 1H NMR (400MHz, CD3OD) δ7.79 (d, J = 10Hz, 1H), 7.67 (s, 1H), 5.68-5.39 (m, 4H), 4.67-4.51 (m, 2H), 3.45-3.35 (m, 1H), 3.30- 3.28(m,1H),2.74-2.71(m,1H),2.48(s,3H),2.38-2.19(m,1H),2.20(s,3H),1.99-1.96(m,2H),1.03(t,J=7.4Hz,3H).

[0199] Example 4: Synthesis of P9

[0200] ((1S, 9S) -1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1,2,3,9,10,12,13,15-octahydrobenzopyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl) methyl acetate 2,2,2-trifluoroacetate.

[0201] At 0 ° C, to (1'R, 9'S) -1-acetyl -9'- ethyl -5'- fluoro -9'- hydroxy -4'- methyl -12'-, 15'- dihydro -2'- spiro [aziridine -2'- benzo [d] pyrano [3', 4': 6, 7] indolizino [1, 2-b] quinoline] -10'-, 13' (3'H, 9'H) - dione (10 mg, 0.02 mmol) in H2O (0.5 mL) and ACN (2 mL) in a solution of TFA (0.5 mL). After addition, the mixture was stirred at 25 ° C for 2 hours. LCMS showed that the reaction was complete. The mixture was concentrated to give the product, which was purified using C18 (0-70% ACN in H2O) to give ((1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1,2,3,9,10,12,13,15-octahydrobenzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)acetate methyl 2,2,2-trifluoroacetate (4.10 mg, 33% yield) as a light yellow solid.

[0202] Characterization data of P9:

[0203] LC-MS (ESI) m / z: 507.8 [M+H] + .

[0204] 1H NMR (400MHz, CD3OD) δ7.81 (d, J = 10.4Hz, 1H), 7.69 (s, 1H), 5.61-5.78 (m, 2H), 5.45-5.41 (m, 2H), 4.65-4.62 (m, 1H), 4.53-4.50 (m, 1H), 3.40-3.9 2(m,1H),3.28-3.23(m,1H),2.80-2.66(m,1H),2.49(s,3H),2.46-2.34 (m,1H),2.33(s,1H),2.19(s,3H),1.99-1.96(m,2H),1.02-0.99(m,3H).

[0205] Example 5: Synthesis of P12, P13, P55, and P56

[0206] (1R,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1-vinyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizine[1,2-b]quinoline-10,13-dione and (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1-vinyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizine[1,2-b]quinoline-10,13-dione.

[0207] Step 1: Synthesis of N,N'-(3-fluoro-4-methyl-8-oxo-7-(2-(phenylsulfinyl)ethyl)-5,6,7-8-tetrahydronaphthalene-1,7-diyl) diacetamide

[0208] Under argon, to a solution of N,N'-(3-fluoro-4-methyl-8-oxy-5,6,7,8-tetrahydronaphthalene-1,7-diyl)diethylamide (1,4.0 g, 13.69 mmol) in THF (30 mL) was added NaH (1.6 g, 68.45 mmol) with stirring at 0°C. Vinylphenyl sulfoxide (3.1 g, 20.54 mmol) was then added dropwise at the same temperature. The reaction mixture was stirred at room temperature for 6 hours. After completion, the reaction was quenched with ice water and extracted with 5% MeOH in chloroform. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product, which was purified by flash column chromatography on silica gel (ethyl acetate:heptane = 4:1 to 9:1) to obtain the product (4.4 g, 65% yield).

[0209] LC-MS (ESI) m / z: 445.28 [M+H] + .

[0210] 1 H-NMR (400MHz; DMSO-d6): δ11.2(d,J=15.2Hz,1H),8.20(m,2H),7.55(m,5H),3.19-3.13(m,1H),2.88 (m,2H),2.71(m,1H),2.12(d,J=2.0Hz,3H),2.07(s,3H),1.87(m,4H),1.74(d,J=2.0Hz,3H).

[0211] Step 2: Synthesis of N, N'-(3-fluoro-4-methyl-8-oxo-7-vinyl-5,6,7,8-tetrahydronaphthalene-1,7-diyl) diacetamide

[0212] N,N'-(3-Fluoro-4-methyl-8-oxyl-7-(2-(phenylsulfinyl)ethyl)-5,6,7,8-tetrahydronaphthalene-1,7-diyl)diethylamide (4.4 g, 9.90 mmol) was dissolved in toluene (20 mL) and stirred at 140°C under argon for 16 hours. Completion was monitored by TLC. The resulting reaction was quenched with ice water and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure to afford a crude residue, which was purified by silica gel column chromatography using 20-40% ethyl acetate / heptane as the eluent (2.5 g, 79% yield).

[0213] LC-MS (ESI) m / z: 319.1 [M+H] + .

[0214] 1 H-NMR (400MHz; DMSO-d6): δ11.57(s,1H),8.34(s,1H),8.28(d,J=12.8Hz,1H),6.05(dd,J=17.6Hz,10.8Hz,1H),5.30(d,J=10.4Hz,1H),5 .15(d,J=17.6Hz,1H),3.03-2.96(m,1H),2.81-2.73(m,1H),2.67-2.59(m,1H),2.15(s,3H),2.14-2.11(m,1H),2.10(s,3H),1.82(s,3H).

[0215] Step 3: Synthesis of N-(8-amino-6-fluoro-5-methyl-1-oxo-2-vinyl-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide

[0216] To a solution of N,N'-(3-fluoro-4-methyl-8-oxy-7-vinyl-5,6,7,8-tetrahydronaphthalene-1,7-diyl)diethylamide (7 g, 22.01 mmol) in MeOH (15 mL) was added 2N HCl (4 mL) with stirring at 0°C, and the mixture was stirred at 70°C for 8 hours, and the reaction was monitored by TLC. After completion of the reaction, the reactants were azeotroped with methanol under reduced pressure until the water was evaporated and submitted to LCMS analysis. The crude product was triturated twice with diethyl ether and used in the next step without further purification. (3.8 g, 62% yield).

[0217] LC-MS (ESI) m / z: 277.05 [M+H] + .

[0218] 1 H-NMR (400MHz; DMSO-d6): δ7.96(s,1H),6.39(d,J=12.8Hz,1H),5.99(dd,J=17.6Hz,10.8Hz,2H),5.23(d,J=10.8Hz,1H) ,5.02(d,J=17.6Hz,1H),3.17(s,1H),2.86-2.81(m,1H),2.69-2.59(m,2H),2.21-2.18(m,1H),1.95(s,3H),1.83(s,3H).

[0219] Step 4: Synthesis of N-((1R,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1-vinyl-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizine[1,2-b]quinolin-1-yl)acetamide and N-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1-vinyl-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizine[1,2-b]quinolin-1-yl)acetamide.

[0220] Under argon protection at room temperature, to a toluene (35 mL) solution of N-(8-amino-6-fluoro-5-methyl-1-oxy-2-vinyl-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide (3.8 g, 11.94 mmol) was added (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-F]indolizine-3,6,10(4H)-one (3.1 g, 11.94 mmol) and Molecular sieves (2 g) were added, followed by the addition of PTSA˙H₂O (453 mg, 2.3 mmol). The reaction was stirred at 140°C for 16 hours using a Dean Stark apparatus and monitored by TLC. After completion, the reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The crude product was purified by silica gel flash column chromatography (methanol:dichloromethane = 0:1-1:11) to yield 1.8 g of crude product, including two diastereomers, P55 and P56. LC-MS (ESI) m / z: 504.33 [M+H] + .

[0221] Step 5: Synthesis of (1R,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1-vinyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizine[1,2-b]quinoline-10,13-dione and (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1-vinyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizine[1,2-b]quinoline-10,13-dione

[0222] At room temperature, N-((1R, 9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1-vinyl-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizine[1,2-b]quinolin-1-yl)acetamide and N-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy- A mixture of 4-methyl-10,13-dioxo-1-vinyl-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)acetamide (1.8 g, 5.6 mmol) was dissolved in H2O (5 mL), MsOH (10 mL) was added, and the mixture was stirred at 130°C for 24 h. LCMS showed that the reaction was complete. The mixture was concentrated to obtain a crude product, which was purified by preparative high performance liquid chromatography (0-50%). The reaction mixture was purified by centrifugation with 1% paraffin wax and purified with CH3CN / H2O) to afford (1R,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1-vinyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizine[1,2-b]quinoline-10,13-dione (24 mg, 0.72% yield) as a white solid and (1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1-vinyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizine[1,2-b]quinoline-10,13-dione (22 mg, 0.72% yield) as a white solid.

[0223] Characterization data of P12:

[0224] LC-MS (ESI) m / z: 462.3 [M+H] + .

[0225] 1 H-NMR (400MHz; DMSO-d6): 8.98 (bs, 2H), 7.92 (d, J=12.8Hz, 1H), 7.35 (s, 1H), 6.56 (s, 1H), 6.38 (dd, J= 17.2Hz,10.8Hz,1H),5.66(d,J=10.4Hz,1H),5.50-5.29(m,4H),3.22-3.14(m, 2H), 2.53 (s, 2H), 2.49-2.39 (m, 4H), 1.90-1.84 (m, 2H), 0.87 (t, J = 7.2Hz, 3H).

[0226] Characterization data of P13:

[0227] LC-MS (ESI) m / z: 462.4 [M+H] + .

[0228] 1 H-NMR (400MHz; DMSO-d6):9.08(bs,2H),7.93(d,J=10.8Hz,1H),7.36(s,1H),6.54(s,1H),6.36(dd,J=17.6Hz,6.4Hz,1H),5.66(d,J =11.2Hz,1H),5.51-5.29(m,4H),3.25-3.14(m,2H),2.45-2.42(m,5H),2.32-2.29(m,1H),1.91-1.83(m,2H),0.87(t,J=7.2Hz,3H).

[0229] Example 6: Synthesis of P21

[0230] Synthesis of N-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3,4':6,7]indolyl[1,2-b]quinolin-1-yl)-2-hydroxyacetamide

[0231] Steps 1 and 2: Dissolve P2 (9 mg, 0.016 mmol, 1 eq) and triethylamine (3.24 mg, 0.032 mmol, 2 eq) in anhydrous DMF (1 mL). Add 2-((tert-butyldimethylsilyl)oxy)acetic acid (3.04 mg, 0.016 mmol, 1 eq) and HATU (12.2 mg, 0.032 mmol, 2 eq). Stir at room temperature for 2.5 hours. LCMS indicates the reaction is complete. Add triethylamine trihydrofluoride (0.5 mL) to remove the TBS protecting group. Purify by preparative HPLC to yield 2.78 mg (33.1% yield) as a white solid.

[0232] Characterization data of P21:

[0233] LC-MS (ESI) m / z: 524 [M+H] + .

[0234] Example 7: Synthesis of P25

[0235] Synthesis of (S)-N-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizine[1,2-b]quinolin-1-yl)-2-hydroxypropionamide

[0236] P2 (15 mg, 0.027 mmol, 1 eq) and triethylamine (27 mg, 0.27 mmol, 10 eq) were added to anhydrous DMF (1 mL), followed by (S)-2-hydroxypropionic acid (12 mg, 0.134 mmol, 5 eq) and HATU (50.9 mg, 0.27 mmol, 2 eq). The mixture was stirred at room temperature for 2.5 hours. LCMS indicated the reaction was complete. Purification by preparative HPLC afforded a white solid (3 mg, 12.4% yield).

[0237] Characterization data of P25:

[0238] LC-MS (ESI) m / z: 538 [M+H] + .

[0239] Example 8: Synthesis of P39

[0240] Synthesis of N-((1R,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1-vinyl-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)-2-hydroxyacetamide

[0241] To a solution of P12 (3 mg, 0.06 mmol), 2-hydroxyacetic acid (1.2 mg, 0.016 mmol), and HATU (6 mg, 0.016 mmol) in anhydrous DMF (0.20 mL) was added DIEA (5.6 μL, 0.032 mmol). After complete addition, the mixture was stirred at room temperature overnight. Purification by preparative HPLC afforded the desired product (1.0 mg, 29.6% yield) as a yellow solid.

[0242] Characterization data of P39:

[0243] LC-MS (ESI) m / z: 560.22 [M+H] + .

[0244] 1H NMR(400MHz,DMSO-d6)δ8.61(s,1H),7.82-7.80(m,1H),7.33(s,1H),7.22(s,1H),7.09(s,1H),6.97(s,1H),6.52(m,1H),5.43-5.41(m,1H), 5.26-5.23(s,1H),5.06-5.01(m,1H),3.98-3.95(m,1H),2.81-2.62(m ,2H),2.38(s,3H),2.00-1.76(m,3H),1.24(s,3H),0.91-0.87(m,3H).

[0245] Example 9: Synthesis of P43

[0246] (S)-9-Ethyl-3,3,5-trifluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzopyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione.

[0247] Step 1: Synthesis of 1,1,7-trifluoro-8-methyl-5-nitro-1,2,3,4-tetrahydronaphthalene.

[0248] To 7-fluoro-8-methyl-5-nitro-3,4-dihydronaphthalen-1(2H)-one (1) (2.0 g, 8.944 mmol) was added DAST (20 mL) at 0°C. The reaction was stirred at 70°C for 16 hours and monitored by TLC. After completion of the reaction, the reaction was quenched with saturated aqueous NaHCO₃ and extracted with ethyl acetate (2 × 15 mL). The organic phase was concentrated under reduced pressure and the crude product (2.4 g) was purified by flash silica gel column chromatography to obtain a sticky brown solid (1.7 g, 73% yield).

[0249] 1 H-NMR (400MHz; DMSO-d6): δ8.07 (d, J = 9.6 Hz, 1H), 2.95-2.90 (m, 2H), 2.45 (d, J = 1.6 Hz, 3H), 2.39-2.32 (m, 2H), 1.84-1.79 (m, 2H).

[0250] Step 2: Synthesis of 3,5,5-trifluoro-4-methyl-5,6,7,8-tetrahydronaphthalen-1-amine.

[0251] To a solution of 1,1,7-trifluoro-8-methyl-5-nitro-1,2,3,4-tetrahydronaphthalene (1.7 g, 6.99 mmol) in MeOH (5 mL) were added H₂O (5 mL), Fe (858 mg, 15.37 mmol), and N₄Cl (2.24 g, 41.94 mmol) at room temperature. The reaction mixture was stirred at 70°C for 2 hours, and the reaction progress was monitored by TLC. After completion of the reaction, the reaction was diluted with ethyl acetate, filtered through celite, and washed with H₂O. The organic phase was concentrated under reduced pressure to obtain the crude product (1.4 g, yield: 94%) as a brown viscous substance.

[0252] 1 H-NMR (400MHz; DMSO-d6): δ6.49 (d, J = 12.4Hz, 1H), 5.18 (s, 2H), 2.43-2.33 (m, 2H), 2.25-2.11 (m, 5H), 1.99-1.82 (m, 2H).

[0253] Step 3: Synthesis of N-(3,5,5-trifluoro-4-methyl-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide

[0254] To a solution of 3,5,5-trifluoro-4-methyl-5,6,7,8-tetrahydronaphthalene-1-amine (1.4 g, 6.511 mmol) in dichloromethane (10 mL) was added DIPEA (3.4 mL, 19.53 mmol) and Ac2O (1.84 mL, 19.53 mmol) at 0°C. The reaction mixture was stirred at room temperature for 2 hours and the reaction was monitored by TLC. After completion of the reaction, the reactant was diluted with saturated aqueous NaHCO3 and extracted with dichloromethane. The organic phase was concentrated under reduced pressure to obtain the crude product (1.2 g, yield: 71.8%) as a brown viscous oil.

[0255] LC-MS (ESI) m / z: 258.03 [M+H] + .

[0256] 1 H-NMR (400MHz; DMSO-d6): δ9.40 (s, 1H), 7.45 (d, J = 11.2Hz, 1H), 2.64 (m, 2H), 2.34-2.22 (m 5H), 2.07 (s, 3H), 1.84-1.79 (m, 2H).

[0257] Step 4: Synthesis of N-(3,5,5-trifluoro-4-methyl-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide

[0258] To a solution of N-(3,5,5-trifluoro-4-methyl-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (4) (1.1 g, 4.28 mmol) in acetone (20 mL) was added MgSO4 (15% aqueous solution) (3.2 mL) and KMnO4 (993 mg, 17.12 mmol) at 0°C. The reaction was stirred at room temperature for 16 hours and monitored by TLC. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and the crude solid (1.8 g) was purified by flash silica gel column chromatography to give a white solid (800 mg, yield: 69%).

[0259] 1 H-NMR (400MHz; DMSO-d6): δ11.95 (s, 1H), 8.57 (d, J = 13.2 Hz, 1H), 2.87-2.84 (m, 2H), 2.77-2.66 (m, 2H), 2.37 (d, J = 2.4 Hz, 3H), 2.19 (s, 3H).

[0260] Step 5: Synthesis of 8-amino-4,4,6-trifluoro-5-methyl-3,4-dihydronaphthalen-1(2H)-one

[0261] To a solution of N-(3,5,5-trifluoro-4-methyl-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (200 mg, 0.73 mmol) in methanol (5.0 mL) was added dropwise 2(N)HCl (0.5 mL) at 0°C. The reaction was stirred at 80°C for 1.5 hours. The reaction was monitored by TLC. After completion of the reaction, the crude product was concentrated and slurried with diethyl ether to afford a red solid (120 mg, 71% yield).

[0262] LC-MS (ESI) m / z: 230.01 [M+H] + .

[0263] 1 H-NMR (400MHz; CDCl3): δ6.57 (bs, 2H), 6.42 (d, J = 11.6Hz, 1H), 2.79-2.76 (m, 2H), 2.59-2.50 (m, 2H), 2.33-2.31 (m, 3H).

[0264] Step 6: Synthesis of (S)-9-ethyl-3,3,5-trifluoro-9-hydroxy-4-methyl-1,2,3,9,12,15-hexahydro-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione

[0265] To a stirred solution of 8-amino-4,4,6-trifluoro-5-methyl-3,4-dihydronaphthalen-1(2H)-one (120 mg, 0.52 mmol) in toluene was added (S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione (152 mg, 0.63 mmol), followed by PTSA (45 mg, 0.26 mmol). The reaction mixture was heated at 130°C for 5 hours. The reaction was monitored by TLC. After completion of the reaction, the mixture was concentrated under reduced pressure and the crude product was purified by flash silica gel column chromatography (elution with ethyl acetate:hexane = 1:1) to obtain a light pink solid (44 mg, yield: 18%).

[0266] LC-MS (ESI) m / z: 457.25 [M+H] + .

[0267] 1 H-NMR (400MHz; DMSO-d6): δ8.11(d,J=10.8Hz,1H),7.32(s,1H),6.54(s,1H),5.44(s,2H),5.30(s ,1H),3.33-3.32(m,2H),2.74-2.67(m,2H),2.63(s,3H),1.92-1.84(m,2H),0.87(t,J=7.2Hz,3H).

[0268] Example 10: Synthesis of P53

[0269] Synthesis of (1s,3S)-N-((1R,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1-vinyl-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)-3-hydroxycyclobutane-1-carboxamide

[0270] P12 (3 mg, 0.006 mmol), (1S,3S)-3-hydroxycyclobutane-1-carboxylic acid (1.2 mg, 0.01 mmol), and HATU (6 mg, 0.016 mmol) were dissolved in anhydrous DMF (200 μL), and DIEA (5.6 μL, 0.032 mmol) was added. The reaction was stirred at room temperature overnight. LCMS indicated the reaction was complete, and the desired product was purified by preparative HPLC to yield the product (1.0 mg, 28% yield) as a yellow solid.

[0271] Characterization data of P53:

[0272] LC-MS (ESI) m / z: 560.22 [M+H] + .

[0273] 1 H NMR(400MHz,DMSO-d6)δ8.61(s,1H),7.82-7.80(m,1H),7.33(s,1H),7.22(s,1H),7.09(s,1H),6.97(s,1H),6.52(m,1H),5.43-5.41(m,1H), 5.26-5.23(s,1H),5.06-5.01(m,1H),3.98-3.95(m,1H),2.81-2.62(m ,2H),2.38(s,3H),2.00-1.76(m,3H),1.24(s,3H),0.91-0.87(m,3H).

[0274] Example 11: Synthesis of P54

[0275] Synthesis of (1R,3R)-n-((1R,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxy-1-vinyl-2,3,9,10,13,15-hexahydro-1h,12h-benzo[de]pyrano[3,4':6,7]indolyl[1,2-b]quinolin-1-yl)-3-hydroxycyclobutane-1-carboxamide

[0276] P12 (3 mg, 0.006 mmol), (1R,3R)-3-hydroxycyclobutane-1-carboxylic acid (1.2 mg, 0.01 mmol), and HATU (6 mg, 0.016 mmol) were dissolved in anhydrous DMF (0.20 mL), and DIEA (5.6 μL, 0.032 mmol) was added. The reaction was stirred at room temperature overnight. LCMS indicated the reaction was complete, and the desired product was purified by preparative HPLC to yield the product (0.86 mg, 24% yield) as a yellow solid.

[0277] Characterization data of P54:

[0278] LC-MS (ESI) m / z: 560.22 [M+H] + .

[0279] 1H NMR(400MHz,DMSO-d6)δ8.55(s,1H),7.82-7.80(m,1H),7.33(s,1H),7.22(s, 1H),7.09(s,1H),6.96(s,1H),6.53-6.51(m,1H),6.16-6.09(m,1H),5.41(s,1 H),5.26-5.23(m,1H),5.07-5.00(m,1H),4.18-4.22(m,1H),2.94(s,33H),2.3 8(s,3H),2.00-1.76(m,3H),1.24(s,3H)1.08-1.05(s,3H),0.91-0.87(m,3H).

[0280] Example 12: Synthesis of P57

[0281] Synthesis of N-((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)-3,3-trifluoro-2-hydroxypropionamide

[0282] P2 (20 mg, 0.036 mmol, 1 eq) and triethylamine (36 mg, 0.36 mmol, 10 eq) were dissolved in anhydrous DMF (1 mL). (S)-3,3,3-trifluoro-2-hydroxypropionic acid (25.6 mg, 0.18 mmol, 5 eq) and HATU (67.6 mg, 0.18 mmol, 2 eq) were added. The mixture was stirred at room temperature for 2.5 hours. LCMS indicated the reaction was complete. Purification by preparative HPLC afforded the product (3 mg, 14% yield) as a white solid.

[0283] Characterization data of P57:

[0284] LC-MS (ESI) m / z: 592 [M+H] + .

[0285] 2. Synthesis of intermediates

[0286] Example 13: Synthesis of K1

[0287] (S)-10-Benzyl-23-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-6,9,12,15,18-pentaoxo-3-oxo-5,8,11,14,17-pentaazatribenzoic acid.

[0288] Step 1: Synthesis of methyl (2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)acetamido)acetate.

[0289] To a solution of 2-(2-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)acetamido)acetic acid (20.0 g, 56.5 mmol) in THF (600 mL) and Tol (200 mL) was added Pb(OAc)4 (34.7 g, 78.3 mmol) and pyridine (5.4 mL) at room temperature. After addition, the mixture was stirred at 75 ° C for 12 hours. LCMS showed that the reaction was complete. The mixture was filtered and concentrated to give the crude product, which was purified by silica gel flash column chromatography (0-100% ethyl acetate / petroleum ether) to give methyl (2-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)acetamido)acetate (13.6 g, 66% yield) as a white solid.

[0290] LC-MS (ESI) m / z: 390.9 [M+Na] + .

[0291] Step 2: Synthesis of 1-(9H-fluoren-9-yl)-3,6-dioxo-2,9-dioxa-4,7-diazaundecane-11-(4-nitrophenyl)benzyl carbonate

[0292] To a solution of methyl (2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)acetamido)acetate (6.60 g, 17.9 mmol) in THF (150 mL) at 0°C were added benzyl 2-hydroxyacetate (5.95 g, 35.8 mmol) and PTSA (1.04 g, 6.05 mmol). After the addition was complete, the mixture was stirred at room temperature for 4 hours. TLC indicated the reaction was complete. The mixture was added to H2O (150 mL) and extracted with ethyl acetate (150 mL x 3). The organic phase was separated, washed with saturated brine (80 mL), dried over anhydrous Na2SO4, filtered and concentrated to give the crude product, which was purified by flash column chromatography on silica gel (0-80% ethyl acetate in petroleum ether) to give 1-(9H-fluoren-9-yl)-3,6-dioxo-2,9-dioxa-4,7-diazaundecane-11-oic acid benzyl ester (4.9 g, 58% yield) as a white solid.

[0293] 1H NMR (400MHz, DMSO-d6): δ8.79-8.73(m,1H),7.89(d,J=8.0Hz,2H),7.71(d,J=8.0Hz,2H),7.60-7.50(m,1H),7.33 -7.42(m,9H),5.75(s,1H),4.63(d,J=8.0Hz,2H),4.15-4.30(m,5H),3.63(d,J=8.0Hz,2H),3.18(d,J=4.0Hz,1H).

[0294] Step 3: Synthesis of benzyl 2-((2-aminoacetamido)methoxy)acetate.

[0295] To a solution of benzyl 1-(9H-fluoren-9-yl)-3,6-dioxo-2,9-dioxa-4,7-diazaundecane-11-oate (4.00 g, 8.40 mmol) in DMF (20 mL) was added piperidine (4 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 hours and then concentrated in vacuo to give crude benzyl 2-((2-aminoacetamido)methoxy)acetate (5.0 g, crude product) as a white solid, which was used directly in the next step without further purification.

[0296] Step 4: Synthesis of 4-nitrophenyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)acetamide)acetate.

[0297] To a solution of 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)acetamido)acetic acid (50.0 g, 141 mmol) in THF (800 ml) was added 4-nitrophenol (49.1 g, 353 mmol) and DCC (72.7 g, 353 mmol) at room temperature. After the addition was complete, the mixture was stirred at room temperature for 12 hours. LCMS showed the reaction was complete. The mixture was filtered to give 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)acetamido)acetate (42.0 g, 63%) as a white solid, which was used in the next step without further purification.

[0298] LC-MS (ESI) m / z: 476.2 [M+H] + .

[0299] Step 5: Synthesis of (S)-11-benzyl-1-(9H-fluoren-9-yl)-3,6,9-trioxo-2-oxo-4,7,10-triazadodecane-12-oic acid

[0300] To a solution of 4-nitrophenyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)acetamido)acetate (22.0 g, 46.3 mmol) in THF (300 mL) was added a solution of NaCO (7.94 g, 92.6 mmol) in HO (99 mL) at room temperature, followed by (S)-2-amino-3-phenylpropionic acid (6.11 g, 37.1 mmol). The resulting mixture was stirred at room temperature for 12 hours. LCMS indicated the reaction was complete. HO (100 mL) was added to the mixture, which was extracted with ethyl acetate (200 mL). The organic phase was separated, dried over anhydrous Na2SO4, filtered and concentrated to give the crude product, which was purified by flash column chromatography on silica gel (0-15% methanol in dichloromethane) to give (S)-11-benzyl-1-(9H-fluoren-9-yl)-3,6,9-trioxo-2-oxo-4,7,10-triazadodecane-12-oic acid (11 g, 59% yield) as a white solid.

[0301] LC-MS (ESI) m / z: 501.9 [M+H] + .

[0302] Step 6: Synthesis of (S)-benzyl 11-benzyl-1-(9H-fluoren-9-yl)-3,6,9,12,15-pentaoxo-2,18-dioxo-4,7,10,13,16-pentaazaeicosanoate.

[0303] To a solution of (S)-11-benzyl-1-(9H-fluoren-9-yl)-3,6,9-trioxy-2-oxa-4,7,10-triazadodecane-12-oic acid (5.00 g, 9.98 mmol) and HATU (7.58 g, 19.9 mmol) in DMF (20 mL) was added benzyl 2-((2-aminoacetamido)methoxy)acetate (5.01 g, 19.8 mmol) at 0°C. After the addition was complete, the mixture was stirred at room temperature for 1 hour. LCMS indicated the reaction was complete. The mixture was concentrated to give the crude product, which was purified by flash column chromatography on silica gel (0-10% methanol / dichloromethane) to give (S)-benzyl 11-benzyl-1-(9H-fluoren-9-yl)-3,6,9,12,15-pentaoxo-2,18-dioxo-4,7,13,13,16-pentaazaeicosanoic acid salt (1.00 g, 14% yield) as a yellow solid.

[0304] LC-MS (ESI) m / z: 569.9 [M+H] + .

[0305] Step 7: Synthesis of (S)-11-benzyl-1-(9H-fluoren-9-yl)-3,6,9,12,15-pentaoxo-2,18-dioxo-4,7,10,13,16-pentaazaiconic acid.

[0306] To a solution of (S)-benzyl 11-benzyl-1-(9H-fluoren-9-yl)-3,6,9,12,15-pentaoxo-2,18-dioxo-4,7,10,13,16-pentaazaeicosane-20-oic acid salt (1.00 g, 1.36 mmol) in methanol (20 mL) was added Pd / C (10% water, 100 mg). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was filtered and the filtrate was concentrated under vacuum to give the crude product (S)-11-benzyl-1-(9H-fluoren-9-yl)-3,6,9,12,15-pentaoxo-2,18-dioxo-4,7,10,13,16-pentaazaeicosane-20-oic acid (900 mg crude product) as a yellow solid, which was used directly in the next step without further purification.

[0307] LC-MS (ESI) m / z: 569.8 [M+H] + .

[0308] Step 8: Synthesis of (S)-16-amino-10-benzyl-6,9,12,15-tetraoxo-3-oxa-5,8,11,14-tetraazahexadecane-1-oic acid

[0309] To (S)-benzyl (S) -11-benzyl -1- (9H- fluorenes -9- bases) -3,6,9,12,15- five oxo -2,18- dioxo -4,7,10,13,16- five aza eicosane -20- acid (900mg, 1.39mmol) in DMF (10mL) solution was added TEA (2mL) at room temperature. The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was filtered and the filtrate was concentrated under vacuum to give the crude product (S) -16- amino -10- benzyl -6,9,12,15- tetraoxo -3- oxa -5,8,11,14- tetraaza hexadecane -1- acid (1.50g, crude product) as a yellow solid, which was used directly in the next step without further purification.

[0310] LC-MS (ESI) m / z: 424.2 [M+H] + .

[0311] Step 9: Synthesis of (S)-10-benzyl-23-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-6,9,12,15,18-pentaoxo-3-oxo-5,8,11,14,17-pentaazatriazole-1-carboxylic acid.

[0312] To a solution of (S)-16-amino-10-benzyl-6,9,12,15-tetraoxo-3-oxo-5,8,11,14-tetraazahexadecane-1-oic acid (1.0 g, 2.36 mmol) in DMF (5 mL) at 0°C were added 2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl-6-(2,5-difluoro-2,5-dihydro-1H-pyrrol-1-yl)hexanoate (1.08 g, 3.54 mmol) and N,N-diisopropylethylamine (1.20 g, 9.45 mmol). After the addition was complete, the mixture was stirred at room temperature for 2 hours. LCMS indicated that the reaction was complete. The mixture was concentrated to give the crude product, which was purified by reverse phase flash column chromatography (0-70% acetonitrile / H2O) to afford (S)-10-benzyl-23-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-6,9,12,15,18-pentaoxo-3-oxo-5,8,11,14,17-pentaazatriazole-1-carboxylic acid (201 mg, 14% yield) as a white solid.

[0313] Characterization data of K1:

[0314] LC-MS (ESI) m / z: 617.0 [M+H] + .

[0315] 1 H NMR (400MHz, DMSO-d6): δ8.60-8.50(m,1H),8.32-8.27(m,1H),8.15-7.97(m,3H),7.31-7.11(m,5H),7.00(s,2H),4.61(d,J=6.4Hz,1H),4.54- 4.45(m,1H),3.98(s,2H),3.81-3.53(m,6H),3.10-3.00(m,1H),2.84-2 .74(m,2H),2.11(t,J=7.4Hz,2H),1.55-1.40(m,5H),1.25-1.00(m,3H).

[0316] 3. Synthesis of Drug Linkers

[0317] Example 14: Synthesis of LP1

[0318] N-((S)-10-Benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadec-16-yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide

[0319] Synthesis of LP1

[0320] At 0 ° C, to (1S, 9S) -1-amino-9-ethyl-5-fluoro-9-hydroxy-1- (hydroxymethyl) -4-methyl -1,2,3,9,12,15-hexahydro -10H, 13H- benzo [d] pyrano [3 ', 4 ': 6,7] indolizine [1,2-b] quinoline -10,13- dione (10.00 mg, 0.021 mmol) in DMF (1 mL) solution (S)-10-Benzyl-23-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-6,9,12,15,18-pentaoxo-3-oxo-5,8,11,14,17-pentaazatrienoic acid (40.00 mg, 0.064 mmol), TCFH (18 mg, 0.064 mmol), and NMI (11.00 mg, 0.13 mmol) were added. After addition, the mixture was stirred at room temperature for 2 hours. LCMS showed that the reaction was complete. The mixture was concentrated to give the crude product which was purified by C18 (0-70% ACN in H2O) to give N-((S)-10-benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-1-(hydroxymethyl)-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadec-16yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide (1.05 mg, 5% yield) as a white solid.

[0321] Characterization data of LP1:

[0322] LC-MS (ESI) m / z: 1063.5 [M+H] + .

[0323] 1H NMR (400MHz, DMSO): δ8.58(t,J=5.6Hz,1H),8.30(t,J=7.2Hz,1H),8.13(d,J=7.2Hz,1H),8.08(t,J=6.0Hz,1H),8.02(d,J=5.6Hz,1H ),7.89(d,J=10.4Hz,1H),7.38(s,1H),7.29–7.15(m,6H),6.99(s,2H),6.57-6.53(m,1H),5.57(s,1H),5.52(s,2H),4.60(d,J=6.8H z,2H),4.50-4.49(m,2H),4.19-4.17(m,1H),3.79–3.61(m,5H),3.26–3.15(m,8H),3.07-3.04(m,1H),2.85–2.76(m,1H),2.68(s,1H ),2.39(s,3H),2.31–2.22(m,1H),2.12-2.08(m,2H),2.07-1.90(m,2H),1.54–1.41(m,4H),1.2-1.08(m,3H),0.89(t,J=7.2Hz,3H).

[0324] Example 15: Synthesis of LP3

[0325] N-((S)-10-Benzyl-1-(((1R,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-1-vinyl-2,3,9,10,13,15-hexahydro-1H,12H-benzo[d]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-1,6,9,12,15-pentaoxo-3-oxa-5,8,11,14-tetraazahexadec-16-yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide

[0326] Synthesis of LP3

[0327] P12 (5 mg, 0.0022 mmol), K1 (10 mg, 0.0033 mmol), DMAP (0.65 mg, 0.0011 mmol), and HOAt (7.5 mg, 0.011 mmol) were dissolved in anhydrous DMF (0.50 mL). EDCI (10 mg, 0.011 mmol) was added to the reaction mixture and stirred at room temperature for 2-3 hours. The reaction mixture was purified by preparative HPLC to afford LP3 (4.3 mg, 37.5% yield) as a yellow solid.

[0328] Characterization data of LP3:

[0329] LC-MS (ESI) m / z: 1060.33 [M+H] + .

[0330] 1 H NMR(400MHz, DMSO-d6)δ8.68-8.65(m,1H),8.42(s,1H),8.14-8.12(m,1H),8.07-8.05(m,1H),8.00-8.96(m,1H),7.82-7.79(m, 1H),7.33(s,1H),7.26-7.17(m,6H),7.11(s,1H),6.99(s,1H),6.98(s,2H),6.28-6.21(m,1H),5.40(s,2H),5.27-5.25(m,1H), 5.04-5.01(m,2H),4.65-4.63(m,2H),4.52-4.49(m,2H),3.97-3.91(m,4H),3.78-3,71(m,2H),3.68-3.60(m,2H),3.36-3.34(m ,2H),2.11(S,2H),2.09-2.07(s,2H),1.86-1.84(s,1H),1.49-1.44(s,4H),1.24(s,1H),1.22-1.18(m,2H),0.98-0.86(m,3H).

[0331] Example 16: Synthesis of Compound LP6

[0332] Synthesis of compound LP6

[0333] P12 (3 mg, 0.0065 mmol), (6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl)glycylglycyl-L-phenylalanine glycine (7 mg, 0.013 mmol), DMAP (0.4 mg, 0.0033 mmol), and HOAt (4.5 mg, 0.033 mmol) were added to anhydrous DMF (0.50 mL). EDCI (6 mg, 0.033 mmol) was added to the reaction mixture and stirred at room temperature for 2-3 hours. The reaction mixture was purified by preparative HPLC to afford LP6 (1.6 mg, 25% yield) as a white solid.

[0334] Characterization data of LP6:

[0335] LC-MS (ESI) m / z: 974.4 [M+H] + .

[0336] 1 H NMR(400MHz,DMSO-d6)δ8.67(s,1H),8.14-8.05(m,1H),8.03-7.99(m,1H),7.99-7.91(m,1H),7.81-7.78(m,1H),7 .32(s,1H),7.19-7.11(m,6H),6.99(s,2H),7.26-7.17(m,6H),7.11(s,1H),6.51(s,1H),6.19-6.12(m,1H),5.42- 5.28(m,3H),5.09(s,2H),4.62-4.57(m,1H),4.35-4.47(m,1H),3.85-3.54(m,4H),2.91-2.96(m,2H),2.71-2.68( m,3H),2.38(s,3H),2.08-2.04(m,3H),1.85-1.82(m,2H),1.48-1.41(m,4H),1.24-1.14(m,3H),0.89-0.85(m,3H).

[0337] Example 17: Synthesis of Compound LP7

[0338] Step 1: Synthesis of compound LP7-1

[0339] A mixture of P43 (10 mg, 0.22 mmol), DMAP (16 mg, 0.13 mmol), and triphosgene (5 mg, 0.017 mmol) was placed in a 5 mL EP tube, and DCM (0.5 mL) was added to the mixture. The resulting mixture was stirred at room temperature for 10 minutes. Tert-butyl (2-(methylamino)ethyl)carbamate (4 mg, 0.23 mmol) was then added, and the mixture was stirred for 8 minutes. The mixture was purified by preparative HPLC to afford LP7-1 (8.2 mg, 57% yield) as a white solid.

[0340] LC-MS (ESI) m / z: 658.2 [M+H] + .

[0341] Step 2: Synthesis of compound LP7-2

[0342] HCl / EA (2M, 1 mL) and LP7-1 (4 mg, 0.006 mmol) were added and stirred at room temperature for 30 minutes. TLC showed no starting material. The mixture was concentrated to give LP7-2 as a crude product, which was directly used for the next step without purification.

[0343] Step 3: Synthesis of compound LP7

[0344] To a solution of LP7-2 in DMF (0.5 mL) was added (6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl)glycylglycyl-L-phenylalanine glycine (6 mg, 0.03 mmol), EDCI (6 mg, 0.03 mmol), and HOBT (4 mg, 0.03 mmol). The mixture was stirred at room temperature for 16 hours. LCMS indicated the desired product. Purification by preparative HPLC gave the desired product, LP7 (2.3 mg, 30% yield), as a white solid.

[0345] Characterization data of LP7:

[0346] LC-MS (ESI) m / z: 1068.5 [M+H] + .

[0347] 1 H NMR(400MHz,DMSO-d6)δ8.25-7.96(m,5H),7.24-7.17(m,6H),7.09-7.05(m ,1H),6.98(s,2H),5.47(s,1H),5.33(s,2H),3.66-3.58(m,8H),3,28-3.11 (m,4H),22.79(s,3H),2.77-2.62(m,5H),2.34-2.08(m,5H),1.46-1.48(m, 4H),1.46(s,4H),11.24-1.18(m,2H),0.94-0.90(m,3H),0.86-0.84(m,1H).

[0348] Example 18: Synthesis of Compound LP8

[0349] Synthesis of compound LP8

[0350] P12 (5 mg, 0.011 mmol), (6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl)-D-valine-D-alanine (8.2 mg, 0.022 mmol), DMAP (0.2 mg, 0.016 mmol), and HOAt (15 mg, 0.11 mmol) were dissolved in anhydrous DMF (200 μL), and EDCI (21 mg, 0.11 mmol) was added. The mixture was stirred at room temperature overnight. LP8 was purified by preparative HPLC to afford LP8 (1.0 mg, 11% yield) as a white solid.

[0351] Characterization data of LP8:

[0352] LC-MS (ESI) m / z: 825.28 [M+H]+ .

[0353] 1 H NMR (400MHz, DMSO-d6) δ8.25(s,1H),8.21(d,J=8Hz,1H),7.92(d,J=8Hz,1H),7.80(d,J=12Hz,1H),7.31( s,1H),7.08(s,2H),6.51(s,1H),6.25-6.20(m,1H),5.42(d,J=8Hz,1H),5.28(d,J=8Hz,1H),5.16-5.05(m ,2H),4.32-4.28(m,2H),4.02-3.98(m,2H),2.80(s,2H),2.37(s,3H),2.32(s,2H),2.11(s,1H),1.91-1. 87(m,2H),1.44-1.40(m,2H),1.24-1.16(m,3H),1.07-1.05(m,2H),0.90-0.86(m,3H),0.83-0.79(m,9H).

[0354] Preparation and characterization of antibody-drug conjugates

[0355] The following are examples of methods for preparing and analyzing antibody-drug conjugates. It should be noted that the following examples are merely partial examples and are not limited to the examples described herein. For example, the antibodies described are not limited to the antibodies currently presented but may be any other antibodies.

[0356] Conjugation process for preparing antibody drug conjugates

[0357] Place the monoclonal antibody (1 eq.) in a 0.5 mL centrifuge tube and add 30 mM His-HAc pH 5.5 buffer to dilute the antibody to 5 mg / mL. Add 100 mM EDTA aqueous solution to 5% of the total reaction volume. After vortexing, add 2 mg / mL TCEP aqueous solution (1.5 to 18 eq.) to the mixture for antibody reduction. After vortexing, place the reaction mixture on a thermostatic mixer with heating and cooling at 20°C for 1.5 hours. Add a 10 mg / mL DMSO-dissolved toxin linker solution (4.0 to 20 eq.) to DMSO, making up 20% of the final reaction volume. After vortexing, place the mixture on a thermostatic mixer with heating and cooling at 20°C for 0.5 hours.

[0358] Use 300 mg / mL dextran-coated activated carbon (manufacturer: Sigma) to remove residual toxin linkers in the reaction solution that are not coupled to the antibody. Add 10% volume of activated carbon solution to the reaction solution, mix and shake, and shake at 4°C for 2 hours. Take the supernatant to detect the residual toxin linker content. If the free toxin linker content is greater than 1%, the above process should be repeated several times until the test results meet the standard (usually 3 times of treatment can meet the requirements). After the treatment is completed, the mixture is centrifuged, the supernatant is collected with a syringe and a hydrophilic membrane filter, and the activated carbon is filtered out. The buffer of the desired antibody-drug conjugate is replaced with a suitable storage buffer by 4 ultrafiltrations and stored at -80°C.

[0359] General Characterization Methods for Antibody Drug Conjugates

[0360] (a) RP-HPLC analysis of DAR values ​​of ADC

[0361] High performance liquid chromatography: e2695 high performance liquid chromatography system.

[0362] Chromatographic column: BioResolve RP mAb Polyphenyl (4.6×100 mm, 2.7 μm) (manufacturer: Waters).

[0363] Mobile phase: Mobile phase A (MPA): 0.1% TFA-H2O; Mobile phase B (MPB): 0.1% TFA-ACN; Elution was performed according to the following elution program (35%-45%), wherein, from 0 to 3 min, the volume of mobile phase A was 90%-90%, and the volume of mobile phase B was 10%-10%; from 3 to 5 min, the volume of mobile phase A was 90%-65%, and the volume of mobile phase B was 10%-35%; from 5 to 20 min, the volume of mobile phase A was 5%-0%, and the volume of mobile phase B was 95%-100%; from 24 to 26 min, the volume of mobile phase A was 0%-100%, and the volume of mobile phase B was 100%-0%; from 26 to 30 min, the volume of mobile phase A was 100%-100%, and the volume of mobile phase B was 0%-0%.

[0364] Detection conditions: Set the mobile phase flow rate to 1 ml / min, the detection wavelength to 280 nm, and the column temperature to 65 °C.

[0365] Experimental Procedure: Take 50 μg of the conjugated sample (converted to volume based on concentration), add 5 μL of 1M DTT, and top up with storage buffer to a final volume of 50 μL. Vortex to mix thoroughly. Incubate the treated sample at 37°C for 30 minutes. After returning to room temperature, centrifuge at 12,000 rpm for 5 minutes. Transfer 20 μL of the supernatant to a HPLC instrument and elute using the above elution procedure. Record the chromatogram.

[0366] The DAR value calculation formula is: DAR = (L0 peak area ratio × 0 + L1 peak area ratio × 1 + H0 peak area ratio × 0 + H1 peak area ratio × 1 + H2 peak area ratio × 2 + H3 peak area ratio × 3) / 100 × 2.

[0367] (b) DAR value of ADC analyzed by HIC-HPLC

[0368] High performance liquid chromatography: e2695 high performance liquid chromatography system.

[0369] Column: MabPac TM HIC-Butyl 5 μm 4.6×100 mm (manufacturer: Thermo).

[0370] Mobile phase: Mobile phase A (MPA): 1.5M (NH4)2SO4 + 50mM potassium phosphate (pH 7.0); Mobile phase B (MPB): 50mM sodium phosphate (pH 7.0) / isopropanol (75:25V / V); Elution was performed according to the following elution program (5%-95%), wherein, from 0 to 2 min, the volume of mobile phase A was 100%-95%, and the volume of mobile phase B was 0%-5%; from 2 to 22 min, the volume of mobile phase A was 95%-5%, and the volume of mobile phase B was 5%-95%; from 22 to 24 min, the volume of mobile phase A was 5%-0%, and the volume of mobile phase B was 95%-100%; from 24 to 26 min, the volume of mobile phase A was 0%-100%, and the volume of mobile phase B was 100%-0%; from 26 to 30 min, the volume of mobile phase A was 100%-100%, and the volume of mobile phase B was 0%-0%.

[0371] Detection conditions: Set the mobile phase flow rate to 1 ml / min, the detection wavelength to 280 nm, and the column temperature to 30 °C.

[0372] Experimental steps: Take 50 μg of the coupled sample (the volume depends on the sample concentration), inject it into the high performance liquid chromatograph, elute using the above elution procedure, and record the chromatogram.

[0373] DAR value calculation formula: DAR = Σ (relative peak area × number of loaded drugs) / 100

[0374] (c) SEC-HPLC analysis of DAR values ​​of ADC

[0375] High performance liquid chromatograph: Agilent 1260 liquid chromatograph.

[0376] Chromatographic column: Waters Xbridge BEH200 SEC (7.8×300 mm, 3.5 μm).

[0377] Mobile phase: 50 mM PB + 200 mM Arg (pH 6.80) + 10% IPA. Elution was performed according to the following elution program: the volume of mobile phase A during 0-30 min was 100%-100%.

[0378] Detection conditions: Set the mobile phase flow rate to 0.5 ml / min, the detection wavelengths to 280 nm and 254 nm, and the column temperature to 26 °C.

[0379] Experimental steps: Take 20 μg of the coupled sample (the volume depends on the sample concentration), inject it into the high performance liquid chromatograph, elute using the above elution procedure, and record the chromatogram.

[0380] Calculation formula: SEC-DAR=C drug / C mAb

[0381] The sum of the absorbance of small molecule drugs and antibodies at 280 nm

[0382] Total absorbance of small molecule drugs at maximum absorption λ(254)

[0383] (d) Free Linker Payload (mol / mol%) analysis by C18-HPLC

[0384] High performance liquid chromatography: e2695 high performance liquid chromatography system.

[0385] Chromatographic column: C18 3.5 μm 4.6×150 mm (manufacturer: Waters).

[0386] Mobile phase: Mobile phase A (MPA): 0.1% TFA-H2O; Mobile phase B (MPB): 0.1% TFA-ACN; Elution was performed according to the following elution program (5%-95%), wherein, from 0 to 30 min, the volume of mobile phase A was 90%-20%, and the volume of mobile phase B was 10%-80%; from 30 to 31 min, the volume of mobile phase A was 20%-90%, and the volume of mobile phase B was 80%-10%; from 31 to 35 min, the volume of mobile phase A was 90%-90%, and the volume of mobile phase B was 10%-10%.

[0387] Detection conditions: Set the mobile phase flow rate to 0.5 ml / min, the detection wavelength to 254 nm, and the column temperature to 30 °C.

[0388] Reagent I preparation example: Measure 30 mL of anhydrous methanol and 50 mL of acetonitrile, weigh 10 g of sodium chloride, mix in a container, stir at room temperature for at least 1 hour, then let it stand for 1 hour. Remove the supernatant, filter it through a 0.22 μm organic membrane, and store at room temperature. It is valid for 3 months.

[0389] Reagent II preparation example: Measure 100 mL of Reagent I, 15 mL of DMSO, and 85 mL of ADC Sample Storage Buffer, mix well in a container, and store at room temperature. The shelf life is 2 months.

[0390] Experimental steps:

[0391] Sample solution preparation:

[0392] 1) Free toxin reference: Take the toxin corresponding to the test sample as the reference and prepare it with the above reagent II to a final concentration of 1.0 mg / ml.

[0393] 2) Take 10 μl of the 1.0 mg / ml toxin reference sample and add it to 90 μl of Reagent II to prepare a concentration of 100 μg / ml. Then, dilute the sample with Reagent II according to the table below to prepare the sample of the desired concentration.

[0394] Note: Inject the samples prepared above to the required concentration into HPLC in ascending order.

[0395] Sample test: Take 85 μg of the coupled sample, mix the sample with 3 μl DMSO for 5 minutes, then take 60 μl of reagent I and add it to the sample system, mix for 5-10 minutes, centrifuge at 2000 rpm for 2 minutes, take 20 μL of the supernatant, inject it into the high performance liquid chromatograph, elute using the above elution procedure, and record the chromatogram.

[0396] The content of free toxin in ADC was calculated based on the calculated standard binary linear regression curve equation.

[0397] Free Drug (mol / mol%) = residual small molecule molar concentration / antibody molar concentration × 100.

[0398] (e) SEC-HPLC analysis of ADC aggregates

[0399] High performance liquid chromatograph: Agilent 1260 liquid chromatograph.

[0400] Chromatographic column: Waters Xbridge BEH200 SEC (7.8×300 mm, 3.5 μm).

[0401] Mobile phase: 50 mM PB + 200 mM Arg (pH 6.80) + 10% IPA. Elution was performed according to the following elution program: the volume of mobile phase A during 0-30 min was 100%-100%.

[0402] Detection conditions: Set the mobile phase flow rate to 0.5 ml / min, the detection wavelength to 280 nm, and the column temperature to 26 °C.

[0403] Experimental steps: Take 20 μg of the coupled sample (the volume depends on the sample concentration), inject it into the high performance liquid chromatograph, elute using the above elution procedure, and record the chromatogram.

[0404] Calculation formula: Monomer purity (%) = A monomer / A total × 100%; polymer purity (%) = A polymer / A total × 100%

[0405] Example 19: Preparation of Antibody Drug Conjugate ADC-1

[0406] n6=7.87

[0407] According to the general coupling process for preparing antibody drug conjugates, TCEP (2 mg / mL, 18.0 eq.) was added to a 50 mM PBS pH 8.0 buffer solution of ciclosporin (1.0 mg, 4.21 mg / mL, 1.0 eq.) and reduced at 20°C for 16 hours; then, LP1 (10 mg / mL, 20.0 eq.) in DMSO was added and the coupling reaction was carried out at 20°C for 0.5 hours. After purification by dextran-coated activated carbon twice, the buffer solution of the desired antibody drug conjugate was ultrafiltered three times to obtain ADC-1 (C ADC (mg / mL): 2.52, V (mL): 0.084, yield 21.2%).

[0408] The following characterization results were obtained using the general characterization method for antibody drug conjugates:

[0409] HIC-DAR: 7.87, SEC purity: 92.98%, Free Linker Payload (mol / mol%): 0.98%.

[0410] Example 20: Preparation of Antibody Drug Conjugate ADC-2

[0411] n6=7.51

[0412] According to the general coupling process for preparing antibody drug conjugates, TCEP (2 mg / mL, 18.0 eq.) was added to trastuzumab (1.0 mg, 38.7 mg / mL, 1.0 eq.) in 50 mM PBS pH 8.0 buffer and reduced at 20°C for 16 hours; then LP1 (10 mg / mL, 20.0 eq.) in DMSO was added and the coupling reaction was carried out at 20°C for 0.5 hours. After purification by dextran-coated activated carbon twice, the buffer of the desired antibody drug conjugate was ultrafiltered three times to obtain ADC-2 (C ADC (mg / mL):3.79, V (mL):0.084, yield 31.8%).

[0413] The following characterization results were obtained using the general characterization method for antibody drug conjugates:

[0414] HIC-DAR: 7.51, SEC purity: 96.7%, Free Linker Payload (mol / mol%): 0.61%.

[0415] Example 21: Preparation of Antibody Drug Conjugate ADC-3

[0416] n6=7.50

[0417] According to the general coupling process for preparing antibody drug conjugates, TCEP (10 mg / mL, 15 eq.) aqueous solution was added to trastuzumab (1.5 mg, 21.07 mg / mL, 1.0 eq.) in 50 mM PBS pH 7.0 buffer and reduced at 22°C for 2 hours; then LP3 (10 mg / mL, 15 eq.) in DMSO was added and the coupling reaction was carried out at 22°C for 1 hour. After purification by dextran-coated activated carbon twice, the buffer of the desired antibody drug conjugate was ultrafiltered three times to obtain ADC-3 (C ADC (mg / mL):6.92, V (mL):0.12, yield 55.4%).

[0418] The following characterization results were obtained using the general characterization method for antibody drug conjugates:

[0419] HIC-DAR: 7.50, SEC purity: 95.71%, Free Linker Payload (mol / mol%): 0.00805.

[0420] Example 22: Preparation of Antibody Drug Conjugate ADC-4

[0421] n6=8.0

[0422] According to the general coupling process for preparing antibody drug conjugates, TCEP (1mM, 15eq.) aqueous solution was added to trastuzumab (1.5mg, 10mg / mL, 1.0eq.) in 20mM PBS pH 7.4 buffer and reduced at 37°C for 1.5 hours; placed on ice for 5 minutes, and then LP6 (1mM, 15.0eq.) DMSO solution was added and the coupling reaction was carried out at 22°C for 1 hour. After purification by dextran-coated activated carbon treatment three times, the buffer of the desired antibody drug conjugate was ultrafiltered five times to obtain ADC-4 (C ADC (mg / mL):10, V (mL):0.1, yield 66%).

[0423] The following characterization results were obtained using the general characterization method for antibody drug conjugates:

[0424] HIC-DAR: 8.0, SEC purity: 98%, Free Linker Payload (mol / mol%): not detected.

[0425] Example 23: Preparation of Antibody Drug Conjugate ADC-5

[0426] n6=8.0

[0427] According to the general coupling process for preparing antibody drug conjugates, TCEP (1mM, 15eq.) aqueous solution was added to trastuzumab (1.5mg, 10mg / mL, 1.0eq.) in 20mM PBS pH 7.4 buffer and reduced at 37°C for 1.5 hours; placed on ice for 5 minutes, and then LP7 (0.62mM, 9.4eq.) in DMSO was added and the coupling reaction was carried out at 22°C for 1 hour. After purification by dextran-coated activated carbon treatment three times, the buffer of the desired antibody drug conjugate was ultrafiltered five times to obtain ADC-5 (C ADC (mg / mL):4.5, V (mL):0.2, yield 60%).

[0428] The following characterization results were obtained using the general characterization method for antibody drug conjugates:

[0429] HIC-DAR: 8.0, SEC purity: 98%, Free Linker Payload (mol / mol%): not detected.

[0430] Example 24: Preparation of Antibody Drug Conjugate ADC-6

[0431] n6=7.92

[0432] According to the general coupling process for preparing antibody drug conjugates, TCEP (10 mg / mL, 15 eq.) aqueous solution was added to trastuzumab (1.5 mg, 21.07 mg / mL, 1.0 eq.) in 50 mM PBS pH 7.0 buffer and reduced at 22°C for 2 hours; then LP8 (10 mg / mL, 15 eq.) in DMSO was added and the coupling reaction was carried out at 22°C for 1 hour. After purification by dextran-coated activated carbon treatment three times, the buffer of the desired antibody drug conjugate was ultrafiltered three times to obtain ADC-6 (C ADC (mg / mL):7.16, V (mL):0.1, yield 47.7%).

[0433] The following characterization results were obtained using the general characterization method for antibody drug conjugates:

[0434] HIC-DAR: 7.92, SEC purity: 98.96%, Free Linker Payload (mol / mol%): not detected.

[0435] Example 25: Preparation of Antibody Drug Conjugate DS-8201a

[0436] n6=7.96

[0437] According to the general coupling process for preparing antibody drug conjugates, TCEP (10 mg / mL, 12 eq.) aqueous solution was added to 50 mM PBS pH 7.0 buffer of trastuzumab (5 mg, 21.07 mg / mL, 1.0 eq.) and reduced at 22°C for 2 hours; then, Deruxtecan (10 mg / mL, 10 eq.) DMSO solution was added and the coupling reaction was carried out at 22°C for 1 hour. After purification by dextran-coated activated carbon twice, the buffer of the desired antibody drug conjugate was ultrafiltered three times to obtain DS-8201a (C ADC (mg / mL): 6.74, V (mL): 0.6, yield 80.9%).

[0438] The following characterization results were obtained using the general characterization method for antibody drug conjugates:

[0439] HIC-DAR: 7.96, SEC purity: 97.7%, Free Linker Payload (mol / mol%): 0.04221.

[0440] Biological evaluation

[0441] 1) Tumor cell proliferation inhibition experiment of camptothecin derivatives

[0442] MDA-MB-231, OV90, and NCI-N87 cells (1500 cells per well, in 80 μl) were added to a 96-well plate at a certain cell concentration. The cells were cultured overnight in a constant temperature incubator (37°C, 5% CO2). A camptothecin derivative solution with a maximum concentration of 2000 nM was prepared and diluted 1:4 in PBS. The diluted solution (20 μl per well) was incubated with the cells (37°C, 5% CO2) for five days, and then CellTitre-Glo reagent (40 μl per well) was added. Fluorescence values ​​were measured using an i3X microplate reader.

[0443] In vitro cell killing activity of the camptothecin derivatives of the present invention (++++: <1 nM; +++: 1-10 nM; ++: 10-200 nM; +: >200 nM)

[0444] The in vitro cell killing activities of P12, P43 and P57 were greater than those of Dxd and ixetine. In addition, the in vitro cell killing activity of P2 was stronger than or equivalent to those of Dxd and ixetine.

[0445] 2) Tumor cell proliferation inhibition experiment of antibody-drug conjugates based on camptothecin derivatives

[0446] PA-1, SK-BR-3, and NCI-N87 cells (1500 cells per well in 80 μl) were plated into 96-well plates at various cell concentrations. The cells were cultured overnight in a constant temperature incubator (37°C, 5% CO2). A camptothecin derivative-antibody drug conjugate solution was prepared at a maximum concentration of 5000 nM and serially diluted 1:4 in PBS. The diluted solution (20 μl per well) was incubated with the cells (37°C, 5% CO2) for five days. CellTitre-Glo reagent (40 μl per well) was then added, and fluorescence was measured using an i3X microplate reader.

[0447] In vitro cell killing activity of ROR1-ADCs (++++: <1 nM; +++: 1-10 nM; ++: 10-200 nM; +: >200 nM).

[0448] In vitro cell killing activity of HER2-ADCs (+++++: <0.1 nM; ++++: 0.1-1 nM; +++: 1-10 nM; ++: 10-200 nM; +: >200 nM).

[0449] All ADCs showed some anti-tumor activity. For example, in SK-BR-3 and NCI-N87 cells, the in vitro cell killing activity of ADC-4 was comparable to that of DS-8201a.

[0450] The camptothecin derivatives and antibody-drug conjugates of the present invention have good in vitro cell-killing activity and better anti-tumor effect.

[0451] The above are only preferred embodiments of the present invention and are not intended to limit the scope of protection of the present invention. Any modifications, equivalent replacements or improvements within the spirit of the present invention are included in the scope of the claims of the present invention.

Claims

1. A camptothecin derivative, characterized in that Its structure is shown in the general formula I: in: R1 and R2 are each independently selected from hydrogen, halogen, hydroxy, cyano, alkyl, alkoxy or cycloalkyl; A is selected from hydrogen, amino, W is selected from cycloalkyl, Y is selected from -C(=O)-, -S(=O)2-, -CHCF3-, -C(=CH2)-, -P(=O)R 10 -、-C(=NR 11 )- or -C(=O)NH-; n=an integer from 0 to 4; Z is selected from hydrogen or -OH; R3 in A is selected from hydrogen or alkyl; R4 and R5 in A are the same or different and are independently selected from hydrogen, trifluoromethyl, alkyl, cycloalkyl, cycloalkyl substituted alkyl, heterocyclyl, aryl or heteroaryl; B is selected from hydrogen, hydroxy, hydroxy-substituted alkyl, alkanoyloxy-substituted alkyl, glycosyl-substituted alkyl, mercapto-substituted alkyl, amino-substituted alkyl, carboxyl-substituted alkyl, ester-substituted alkyl, alkynyl, alkenyl, cyano or cyano-substituted alkyl; R6 and R7 are the same or different and are independently selected from hydrogen, fluorine or alkyl; R8 and R9 are the same or different and are independently selected from hydrogen, fluorine or alkyl; R 10 and R 11 The same or different, and each independently selected from saturated or unsaturated alkyl or aryl.

2. The camptothecin derivative according to claim 1, characterized in that In the general formula I: R1 and R2 are each independently selected from hydrogen, halogen, hydroxy, cyano, alkyl, alkoxy or cycloalkyl; A is selected from hydrogen, amino, Y is selected from -C(=O)-, -S(=O)2-, -CHCF3-, -C(=CH2)-, -P(=O)R 10 -、-C(=NR 11 )- or -C(=O)NH-; n=an integer from 0 to 4; Z is selected from hydrogen or -OH; R3 in A is selected from hydrogen or alkyl; R4 and R5 in A are the same or different and are independently selected from hydrogen, trifluoromethyl, alkyl, cycloalkyl, cycloalkyl substituted alkyl, heterocyclyl, aryl or heteroaryl; B is selected from hydrogen, hydroxy, hydroxy-substituted alkyl, alkanoyloxy-substituted alkyl, glycosyl-substituted alkyl, mercapto-substituted alkyl, amino-substituted alkyl, carboxyl-substituted alkyl, ester-substituted alkyl, alkynyl, alkenyl, cyano or cyano-substituted alkyl; R6 and R7 are the same or different and are independently selected from hydrogen, fluorine or alkyl; R8 and R9 are the same or different and are independently selected from hydrogen, fluorine or alkyl; R 10 and R 11 The same or different, and each independently selected from saturated or unsaturated alkyl or aryl.

3. The camptothecin derivative according to claim 1, characterized in that In the general formula I: R1 is selected from fluorine; R2 is selected from methyl; A is selected from hydrogen, amino, W is selected from cyclobutyl, Y is selected from -C(=O)-, -S(=O)2- or - CHCF3-; n = an integer of 0-3; Z is selected from hydrogen or -OH; R3 in A is selected from hydrogen or methyl; R4 and R5 in A are the same or different and are independently selected from hydrogen, methyl, trifluoromethyl, B is selected from hydrogen, -CH2OH, -CH2OAc, -CH2SH, -CH2NH2, -CH2C(=O)OH, -CH2C(=O)OMe, ethynyl, vinyl, cyano or -CH2CN; R6 and R7 are the same or different and are independently selected from hydrogen or fluorine; R8 and R9 are the same or different and are independently selected from hydrogen or fluorine.

4. The camptothecin derivative according to claim 1, 2 or 3, characterized in that The R4, R5 and the carbon atom to which they are connected constitute a cyclopropyl group.

5. The camptothecin derivative according to claim 1, 2 or 3, characterized in that The R4 and R5 are not hydrogen at the same time.

6. The camptothecin derivative according to claim 1, 2 or 3, characterized in that When B is hydrogen, A is also hydrogen; when A is amino, B is not hydrogen.

7. The camptothecin derivative according to claim 1, characterized in that R3, B in A and the carbon atom to which A and B are connected together and / or the nitrogen atom to which R3 is connected constitute an aziridine group or an azetidine group, and / or, R1 and R2 together with their adjacent carbon atoms form a cycloalkyl or heterocyclic group, and / or, R4 and R5 together with the carbon atom to which they are attached constitute a cycloalkyl group or a heterocycloalkyl group.

8. The camptothecin derivative according to claim 1, characterized in that The compound of general formula I is at least selected from one of the structures shown below:

9. The camptothecin derivative according to any one of claims 1 to 8, characterized in that Also included are prodrugs of the compounds of general formula I, or pharmaceutically acceptable salts, esters, solvates, tautomers, stereoisomers, polymorphs, nitrogen oxides or isotope-labeled substances thereof.

10. Use of the camptothecin derivative according to any one of claims 1 to 9 in the preparation of a medicament for treating cancer.

11. A compound of formula II, characterized in that: M-L1-L2-D General formula Ⅱ Among them, M is selected from and / or, L1 is selected from n1=an integer from 1 to 10, n2=an integer from 1 to 12, n3=an integer from 1 to 10, n4=an integer from 1 to 12; and / or L2 is selected from n5=an integer of 7-24, L2 is connected to A in the general formula I; or L2 is selected from L2 is connected to the O of OH in the general formula I. D is selected from the product group formed by the camptothecin derivative according to any one of claims 1 to 9 losing one or more atoms or groups; In the general formula II, one or two of L1 and L2 are selected.

12. The compound according to claim 11, characterized in that M is selected from and / or L1 is selected from and / or L2 is selected from L2 is connected to A in Formula I; or L2 is selected from L2 is connected to the O of OH in the general formula I.

13. The compound according to claim 11, characterized in that The compound of the general formula II is at least one of the compounds of the following structural formulas, wherein L2 is connected to A in the general formula I: or, The compound of formula II is selected from the following compounds, wherein L2 is connected to O of OH in formula I:

14. The compound according to claim 11, 12 or 13, characterized in that Also included are prodrugs of the compound of general formula II, or pharmaceutically acceptable salts, esters, solvates, tautomers, stereoisomers, polymorphs, nitrogen oxides or isotope labels thereof.

15. Use of a compound according to claim 11, 12, 13 or 14 in the preparation of a medicament for treating cancer.

16. An antibody-drug conjugate of formula III, characterized in that: Ab is an antibody, an antibody fragment or a protein, wherein the antibody is selected from a mouse antibody, a rabbit antibody, a phage display antibody, a yeast display antibody, a chimeric antibody, a humanized antibody, a fully human antibody, an antibody fragment, a bispecific antibody or a multispecific antibody; M-L1-L2-D is selected from the compound of general formula II as described in claim 11, 12 or 13, or its pharmaceutically acceptable salt, ester, solvate, tautomer, stereoisomer, polymorph, nitrogen oxide and / or isotope label; n6 is selected from any value between 1-20. In the general formula III, the carbon-carbon double bond of M in the M-L1-L2-D is connected to the thiol group in the antibody Ab by Michael addition reaction to form a CS bond.

17. The antibody-drug conjugate according to claim 16, characterized in that: The antibody is a monoclonal antibody.

18. The antibody-drug conjugate according to claim 16, characterized in that: The antibody is selected from the group consisting of abciximab, alemtuzumab, anetuzumab, atezolizumab, avelumab, basiliximab, bevacizumab, blinatumomab, brentuximab, catumaxomab, cetuximab, cetuximab, cotuximab, daclizumab, daratumumab, deninutuzumab, denosumab, depatuxizumab, denutumab, durvalumab, elotuzumab, enroku, gebatumumab, gemtuzumab, ibritumomab tiuxetan, indalatuzumab, indoximab, inotuzumab, ipilimumab, labetuzumab, latuzumab, latuximab, rifatuzumab, lovatostatin, The invention relates to the invention to the invention to at least one of the following: anti-CD4 antibodies, anti-CD5 antibodies, anti-CD13 antibodies, and anti-CD30 antibodies, or antigen-binding fragments or immunologically active portions thereof.

19. The antibody-drug conjugate according to claim 16, characterized in that: The antibody is selected from monoclonal antibodies.

20. The antibody-drug conjugate according to any one of claims 16 to 19, characterized in that: n6 is selected from any value between 4 and 10.

21. The antibody-drug conjugate according to claim 20, characterized in that: n6 is selected from any value between 4 and 8.

22. The antibody-drug conjugate according to claim 16, characterized in that: The conjugate is at least one of the structures shown in the following formula: ; Where n6 is any value between 4 and 8.

23. Use of the antibody-drug conjugate of general formula III according to claims 16 to 22 in the preparation of a drug for treating cancer.

24. The method for preparing a camptothecin derivative according to any one of claims 1 to 9, characterized in that: The synthetic route is:

Citation Information

Patent Citations

  • Camptothecin derivative and conjugate thereof

    CN112125915A

  • Camptothecin drug with high-stability hydrophilic linkage unit and conjugate thereof

    CN113827736A

  • Exatecan derivatives and linker-loadings and conjugates thereof

    CN115990269A

  • Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof

    US20210353764A1

  • Camptothecin compound, preparation method therefor, and application thereof

    WO2022166762A1

Cited By

  • Pharmaceutical composition for treatment and / or prevention of cancer

    CN123036312A

  • Pharmaceutical composition for treating and / or preventing cancer

    WO2025206085A1

  • Ligand-drug conjugate comprising hydrophilic linker, intermediate thereof, and use thereof

    WO2026219332A1